ДЕНТАЛЬНАЯ МИНЕРАЛИЗАЦИЯ

Группа изобретений относится к области медицины, а именно к стоматологии. Предлагается способ минерализации эмали зубов, включающий контактирование зубной эмали или повреждения в зубной эмали с белок-солюбилизирующим, белок-разрушающим или белок-гидролизующим агентом перед контактированием зубной эмали с фосфопептид-стабилизированным аморфным кальция фосфатом (АСР) или аморфным кальция фторид фосфатом (ACFP). Фосфопептидом предпочтительно является казеиновый фосфопептид (СРР). Белок-солюбилизирующий, белок-разрушающий или белок-гидролизующий агент выбирают из одного или нескольких веществ группы, состоящей из отбеливателя, детергента, хаотропного агента, протеазы или смеси протеаз. Предпочтительно используют отбеливатель, такой как натрия гипохлорит или пероксид карбамида. Также предлагаются способы минерализации гипоминерализованных повреждений в зубной эмали, вызванных кариесом зубов, флюорозом, дентальной эрозией, и набор для лечения и профилактики указанных состояний, включающий: а) ...

СЕРИНОВЫЕ ПРОТЕИНАЗЫ РЫБ И ИХ ФАРМАЦЕВТИЧЕСКОЕ И КОСМЕТИЧЕСКОЕ ПРИМЕНЕНИЕ

Изобретение относится к области лекарственных средств и касается применения сериновых протеиназ рыб, выбранных из группы, состоящей из трипсина, химотрипсина и любой их смеси, полученной из трески, или имеющей, по меньшей мере, 90% гомологию по аминокислотной последовательности с трипсином или химотрипсином, выделенными из атлантической трески, в качестве лекарственного средства для лечения и/или предупреждения болезней, в патогенез которых вовлекается рецептор-опосредованное связывание. Также предлагается фармацевтическая композиция для лечения и/или предупреждения болезней у человека или животных, в патогенез которых вовлекается рецептор-опосредованное связывание, содержащая эффективное количество указанной сериновой протеиназы и фармацевтически приемлемый растворитель или носитель, и косметическая композиция для удаления мертвой или шелушащейся кожи со здоровой кожи, содержащая эффективное количество указанной сериновой протеиназы рыб. Техническим результатом является применение сериновых ...

КОСМЕТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ОБРАБОТКИ КЕРАТИНОВЫХ ВОЛОКОН, СПОСОБ ИХ ОКРАСКИ, УПАКОВКА НАБОРА ДЛЯ ИХ ОКРАСКИ, СПОСОБЫ ОБРАБОТКИ КЕРАТИНОВЫХ ВОЛОКОН

Изобретение касается косметической композиции для кератиновых волокон, содержащей в пригодной для кератиновых волокон среде: а) фермент типа оксидредуктазы с 2 электронами в присутствии донора для данного фермента, б) анионный амфифильный полимер, содержащий гидрофильное звено и звено в виде аллильного эфира с жирной цепочкой, а также к упаковке набора для окраски волос и способам окраски, перманентной обработки или обесцвечивания волос с использованием данной композиции. Изобретение обеспечивает однородную, хроматографическую окраску, не вызывая повреждений волос. 5 с. и 27 з.п.ф-лы.

ГИАЛУРОНИДАЗА И СПОСОБ ЕЕ ПРИМЕНЕНИЯ

Изобретение относится к биотехнологии и медицине и представляет собой фармацевтический состав для расщепления гиалуроновой кислоты in vivo, содержащий эффективное количество выделенного белка гиалуронидазы, который имеет молекулярный вес 44±1 кДа и содержит аминокислотную последовательность, по меньшей мере на 90% идентичную последовательности SEQ ID NO: 1, SEQ ID NO: 2 и SEQ ID NO: 4, и фармацевтически приемлемый эксципиент, носитель, разбавитель или вспомогательный агент. Изобретение относится также к способу минимизации проявления рубца, включающему местное применение такого фармацевтического состава, а также к способу повышения терапевтической эффективности лекарственного средства, включающему введение пациенту лекарственного средства совместно с фармацевтическим составом. Изобретение позволяет расширить ассортимент средств для улучшения проникновения одновременно вводимого активного вещества через кожу. 7 н. и 35 з.п. ф-лы, 16 ил., 23 табл., 12 пр.

СОСТАВ ДЛЯ СТАБИЛИЗАЦИИ БЕЛКОВ, КОТОРЫЙ НЕ СОДЕРЖИТ ЭКСЦИПИЕНТЫ ИЗ МЛЕКОПИТАЮЩИХ

Группа изобретений относится к области фармацевтики и медицины и касается состава для стабилизации белков и пептидов, который содержит гидрофильный полимер, смесь полиспирта и сахара, где массовое отношение полиспирта к сахару составляет от 2:1 до 5:1 (масс.%), детергент и где состав не содержит стабилизирующих белков. Композиция и набор для лечения заболевания или состояния, вызываемого гиперактивной холинэргической иннервацией мышц или экзокринных желез у пациента, содержит указанный состав и пептид, белок или их смесь. Группа изобретений обеспечивает лучшую стабильность белков в отсутствие стабилизирующих белков. 3 н. и 10 з.п. ф-лы, 4 пр.

ГИАЛУРОНИДАЗА И СПОСОБ ЕЕ ПРИМЕНЕНИЯ

Изобретение относится к области биохимии. Представлены выделенный белок гиалуронидазы, который имеет молекулярный вес приблизительно 44±1 кДа, содержащий аминокислотную последовательность, по меньшей мере, на 90% идентичную последовательности, которая содержит SEQ ID NO: I, SEQ ID NO: 2 и SEQ ID NO: 4, приведенные в описании, а также кодирующая его ДНК. Описан фармацевтический лекарственный состав для повышения проницаемости ткани или уменьшения вязкости соединительной ткани, содержащий эффективное количество выделенной указанной гиалуронидазы и фармацевтически приемлемый эксципиент, носитель, разбавитель или вспомогательный агент. Предложены способы: 1) предотвращения или минимизации образования рубца, включающий местное введение указанного фармацевтического состава; 2) сокращения проявления морщин посредством уменьшения вязкости соединительной ткани, включающие местное введение указанного фармацевтического состава; 3) облегчения дискомфорта или боли, вызванной ревматическим артритом, ...

ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ С ЗАМЕДЛЕННЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ ПОЛОКСАМЕР

Изобретение относится к фармацевтической промышленности и представляет собой термообратимую, термопластическую фармацевтическую композицию, содержащую (а) биологически активный ботулинический токсин; (б) термопластический полоксамер, где полоксамер стабилизирует ботулинический токсин таким образом, что ботулинический токсин сохраняет биологическую активность при высвобождении ботулинического токсина из фармацевтической композиции in vivo, где фармацевтическая композиция может быть приготовлена без содержания любых веществ, содержащихся в крови, таких как альбумин, и поэтому без любых инфицирующих элементов веществ крови, таких как прион. Изобретение обеспечивает высокую стабильность и высокий процент восстановления активности токсина, 4 н. и 14 з.п. ф-лы, 6 пр.

КОМПОЗИЦИЯ ДЛЯ ОКРАСКИ КЕРАТИНОВЫХ ВОЛОКОН, СПОСОБ ИХ ОКРАСКИ, НАБОР ДЛЯ ОКРАСКИ КЕРАТИНОВЫХ ВОЛОКОН

Изобретение относится к композиции для окраски кератиновых волокон, в частности волос, включающей в соответствующем для кератиновых материалов носителе: (а) фермент типа лакказы; (б) анионное поверхностно-активное вещество, выбираемое из группы, состоящей из ацилизетионатов, ацилтауратов, сульфосукцинатов особой структуры, ацилсаркозинатов особой структуры, ацилглютаматов, полиоксиалкиленированных оксикарбоновых кислот и их солей, глюкамидалкилсульфатов, алкилгалактозидуронатов, анионных производных алкилполиглюкозидов, и их смесей; (в) фиксирующийся при окислении краситель; а также к способу окраски волос, при которых используют эту композицию и к набору ее ингредиентов. Изобретение обеспечивает однородное, интенсивное и хроматичное окрашивание, не вызывающее ни значительного разрушения, ни обесцвечивания кератиновых волокон, устойчиво к агрессивным воздействиям. 3 с. и 23 з.п. ф-лы, 1 табл.

КОМПОЗИЦИИ ДЛЯ УХОДА ЗА ПОЛОСТЬЮ РТА И СПОСОБЫ ОТБЕЛИВАНИЯ ЗУБОВ

Изобретение относится к средствам гигиены. Раскрыта композиция для ухода за полостью рта, содержащая приемлемую для применения в полости рта среду-носитель, содержащую, в свою очередь, средство для чистки зубов, представляющее собой пасту, и содержащее источник пероксида водорода, и ускоритель отбеливания средства для ухода за полостью рта, представляющий собой гель и содержащий донор ацильной группы и фермент, который катализирует реакцию между источником пероксида водорода и донором ацильной группы с образованием надуксусной кислоты, при этом гель-ускоритель по существу свободен от полиоловых увлажнителей. Изобретение позволяет получить стабильную композицию с улучшенной эффективностью отбеливания зубов. 12 з.п. ф-лы, 9 табл., 4 пр.

ЖЕВАТЕЛЬНАЯ КОНДИТЕРСКАЯ КОМПОЗИЦИЯ ДЛЯ ЗУБОВ ПРОТИВ ОБРАЗОВАНИЯ ЗУБНОГО НАЛЕТА

Изобретение относится к кондитерской промышленности. Жевательная кондитерская композиция содержит от 0,1 до 3 мас.% фермента, твердый материал основы, не вызывающий кариес подсластитель, вещество, стабилизирующее ферменты, и менее 5 мас.% воды. Фермент выбран из протеаз, которые экстрагируют из фруктовых продуктов и вводят в твердый материал основы композиции при температуре 80°С, причем ферментативная активность протеаз сохраняется в композиции в течение периода по меньшей мере 4 недель при 23°С. Введение фермента в композицию способствует разрушению зубного налета и препятствует его образованию и адгезии на зубной поверхности при потреблении продукта. 12 з.п. ф-лы, 7 табл.

КОМПОЗИЦИЯ ДЛЯ ОКИСЛИТЕЛЬНОЙ ОКРАСКИ КЕРАТИНОВЫХ ВОЛОКОН, СПОСОБ ИХ ОКРАСКИ

Заявка относится к косметической композиции для окислительной окраски кератиновых волокон, включающей в соответствующем для окраски кератиновых волокон носителе (а) фермент типа лакказы; (б) подщелачивающий компонент; (в) фиксирующийся при окислении краситель, а также к способу окраски, при которых используют эту композицию. Изобретение обеспечивает однородное, хроматичное и интенсивное окрашивание волос. 2 с. и 19 з.п. ф-лы.

КОМПОЗИЦИЯ ДЛЯ ОКИСЛИТЕЛЬНОЙ ОКРАСКИ КЕРАТИНОВЫХ ВОЛОКОН И СПОСОБ ОКРАСКИ, ПРИ КОТОРОМ ИСПОЛЬЗУЮТ ЭТУ КОМПОЗИЦИЮ

Изобретением является композиция для окислительной окраски кератиновых волокон, в частности волос, включающая в подходящей для окраски среде окисляющееся основание, 2-амино-4-N-(β -гидроксиэтил)аминоанизол в качестве краскообразующего компонента, фермент типа лакказы, а также способ окраски, при котором используют эту композицию, и набор, включающий компоненты заявленной композиции. Изобретение обеспечивает интенсивную малоселективную окраску волокон, устойчивость к агрессивным факторам. 3 с. и 23 з.п. ф-лы.

СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ СТАРЕНИЯ КОЖИ И РУБЦОВ

Группа изобретений относится к медицине, а именно к косметологии, и может быть использована для лечения старения кожи. Для чего используют средство, содержащее основной фактор роста фибробластов (bFGF) как единственный активный ингредиент, которое вводится внутрикожно или подкожно в место рубца, или в окружающую его часть, например келоида, гипертрофического рубца и рубцовой контрактуры; кроме того, средство также предназначено для лечения одного или более видов старения кожи, выбранных из следующего перечня: морщины на коже, обвисшая кожа, грубая кожа, истончение кожи и снижение упругоэластичности кожи из-за разрыва дермальных тканей или снижения функций фибробластовых клеток. При этом старение кожи является фотостарением, а величина дозы основного фактора роста фибробластов (bFGF) составляет от 0,1 мкг до 1 мг на 1 смкожи, являющейся целью лечения. Изобретения обеспечивают достоверное уменьшение морщин, улучшение структуры кожи, в том числе за счет повышения ее тургора и увеличения объема ...

КОМПОЗИЦИИ ДЛЯ УХОДА ЗА ПОЛОСТЬЮ РТА И СПОСОБЫ ОТБЕЛИВАНИЯ ЗУБОВ

Группа изобретений относится к композиции для ухода за полостью рта. Композиция является однофазной и содержит фермент пергидролазу, который катализирует образование надуксусной кислоты между источником пероксида водорода и донором ацильной группы, безводную матрицу, выполненную с возможностью, по меньшей мере, частичной стабилизации фермента. Безводная матрица содержит указанные источники пероксида водорода и донора ацильной группы, не содержащую воду безводную жидкость и загуститель. Способ стабилизации фермента в композиции для ухода за полостью рта включает приведение в контакт фермента с безводной матрицей. Способ отбеливания зубов включает приведение в контакт композиции для ухода за полостью рта с водой на поверхности зубов, что обеспечивает образование надуксусной кислоты. Группа изобретений обеспечивает устойчивость отбеливающей композиции в условиях ускоренного старения, где потери пероксида водорода минимизированы. 3 н. и 10 з.п. ф-лы, 3 табл., 2 пр.

КОСМЕТИЧЕСКАЯ ИЛИ ДЕРМАТОЛОГИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ МЕСТНОГО ПРИМЕНЕНИЯ В ФОРМЕ ВОДНОЙ И СТАБИЛЬНОЙ ДИСПЕРСИИ ЧАСТИЦ КУБИЧЕСКОГО ГЕЛЯ И ЕЕ ПРИМЕНЕНИЕ

Изобретение относится к области косметологии. Предложена косметическая или дерматологическая композиция в форме водной и стабильной дисперсии частиц кубического геля на основе 3,7,11,15-тетраметил-гексадекан-1,2,3-триола или фитантриола и ее применение для гидратации (увлажнения) кожи. Эта композиция по существу содержит 0,1 - 15 мас.% 3,7,11, 15-тетраметил-гексадекан-1,2,3-триола в расчете на общую массу композиции и 0,1-3 мас.% диспергирующего и стабилизирующего агента в расчете на общую массу композиции, причем вышеуказанный агент выбирают среди водорастворимых при комнатной температуре поверхностно-активных агентов, содержащих насыщенную или нет алифатическую цепь с 8-22 атомами углерода. Эта композиция более стабильна, позволяет включать в нее гидрофильные и/или липофильные действующие начала без проблем совместимости. 2 c. и 29 з.п. ф-лы, 1 табл.

Гидрогель для реминерализации твердых тканей зубов

Изобретение относится к медицине, а именно к стоматологии, и может быть использовано для реминерализации твердых тканей зубов с целью профилактики и лечения кариеса в стадии пятна, гиперестезии твердых тканей зубов. Предлагаемый гидрогель содержит, мас. %: гидроксиапатит 10,0-15,0; ксилитол 10,0-15,0; папаин 3,0-5,0; нитрат калия 3,0-5,0; карбопол 0,5-1,0; раствор натрия гидрооксида 10% 2,0-3,0; сорбиновую кислоту 0,2-0,5; отдушку 0,3-0,5; воду высокоочищенную – остальное. Использование средства обеспечивает повышение кислотоустойчивости эмали, устранение и предупреждение прогрессирования процессов деминерализации твердых тканей зубов, уменьшение повышенной чувствительности, пролонгирование эффекта реминерализации за счет длительного контакта реминерализующего геля с поверхностью твердых тканей зубов, повышение эффективности лечебно-профилактических мероприятий и сокращение сроков их проведения. 4 табл., 4 пр., 2 ил.

КОМПОЗИЦИИ ДЛЯ ВОССТАНОВЛЕНИЯ КОЖИ, СОДЕРЖАЩИЕ АКТИВАТОРЫ ЦИРКАДНЫХ ГЕНОВ И СИНЕРГИЧЕСКУЮ КОМБИНАЦИЮ АКТИВАТОРОВ ГЕНА sirt1

Группа изобретений относится к медицине и касается композиции для ухода за кожей и способа ингибирования повреждения человеческих кератиноцитов, вызванного воздействием агрессивных факторов окружающей среды, и способа репарации повреждения человеческих кератиноцитов вследствие воздействия агрессивных факторов окружающей среды. Указанная композиция, содержит по меньшей мере одно средство, которое стимулирует экспрессию циркадных генов в клетках кожи и по меньшей мере один активатор циркадных генов кератиноцитов и по меньшей мере один активатор гена sirt1 кератиноцитов. Группа изобретений обеспечивает простоту в применении, эффективность, химическую, термодинамическую устойчивость и устойчивость к действию света, безопасность для топического применения, отсутствие побочных эффектов. 4 н. и 15 з.п. ф-лы, 4 пр., 3 ил.

МИНЕРАЛЬНО-ФЕРМЕНТАТИВНЫЙ КОМПЛЕКС ДЛЯ УКРЕПЛЕНИЯ И ОТБЕЛИВАНИЯ ЭМАЛИ ЗУБОВ, КОМПОЗИЦИЯ ДЛЯ ГИГИЕНЫ ПОЛОСТИ РТА И ЗУБНАЯ ПАСТА

Изобретение относится к косметологии, а именно к средствам для укрепления и отбеливания эмали зубов. Минерально-ферментативный комплекс для укрепления и отбеливания эмали зубов характеризуется тем, что содержит гидроксиапатит и танназу при следующем соотношении компонентов: на 100 мас.ч. гидроксиапатита - 0,2-10 ч. танназы. Комплекс также может дополнительно содержать экстракт виноградных косточек. Предлагаются также композиции для гигиены полости рта, включающие в себя данный комплекс, которые могут быть представлены в форме зубной пасты, ополаскивающей композиции, жевательной резинки. Зубная паста, содержащая указанный минерально-ферментативный комплекс, включает также приемлемый носитель, содержащий, предпочтительно, абразивные вещества, увлажнители, загустители, поверхностно-активные вещества и растворители. Сочетание компонентов минерально-ферментативного комплекса обеспечивает достижение очищающего и отбеливающего зубы эффекта наряду с реминерализирующим действием на ткани зубов, ...

ДВУХКОМПОНЕНТНАЯ ЗУБНАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ФЕРМЕНТ

... 1. Двухкомпонентная ферментная композиция средства для чистки зубов, имеющая превосходные характеристики пенообразования, которая содержит первый компонент средства для чистки зубов, содержащий фермент в орально приемлемом носителе, который по существу свободен от ионного поверхностно-активного вещества, и второй компонент средства для чистки зубов, содержащий ионное поверхностно-активное вещество в орально приемлемом носителе, который по существу свободен от фермента, причем первый и второй компоненты поддерживаются отдельно друг от друга до распределения и комбинирования для нанесения на зубы, посредством чего по существу сохраняется активность фермента во время нанесения комбинированных компонентов на зубы во время чистки щеткой. 2. Композиция по п.1, где фермент представляет собой папаин. 3. Композиция по п.1, где фермент представляет собой глюкоамилазу. 4. Композиция по п.1, где ионное поверхностно-активное вещество представляет собой анионное поверхностно-активное вещество. 5. Композиция ...

УЛУЧШЕННАЯ ФЕРМЕНТОМ ПЛЕНКА ДЛЯ ОСВЕЖЕНИЯ ДЫХАНИЯ

... 1. Композиция орально потребляемой пленки для высвобождения в ротовую полость веществ, освежающих дыхание, которая быстро растворяется или разрушается в ротовой полости, композиция, включающая гомогенную смесь фермента и полимера, образующего водорастворимую или диспергируемую в воде пленку. 2. Композиция пленки по п.1, в которой полимер представляет собой гидроксиалкилцеллюлозу. 3. Композиция пленки по п.2, в которой гидроксиалкилцеллюлоза представляет собой гидроксиметилпропилцеллюлозу. 4. Композиция пленки по п.1, в которой диспергируемый в воде полимер присутствует в концентрации от примерно 10 до примерно 60 мас.%. 5. Композиция пленки по п.1, в которой фермент представляет собой фермент протеазу. 6. Композиция пленки по п.5, в которой фермент протеаза представляет собой папаин. 7. Композиция пленки по п.1, в которой фермент присутствует в пленке в концентрации от примерно 0,1 до примерно 5 мас.%. 8. Способ высвобождения в ротовую полость веществ, освежающих дыхание, который включает ...

МНОГОКОМПОНЕНТНЫЕ ОТБЕЛИВАЮЩИЕ КОМПОЗИЦИИ И КОНТЕЙНЕРЫ

... 1. Контейнер для хранения и дозирования композиций для чистки зубов, содержащихся в нем, включающий: ! первый отсек, включающий первую композицию для чистки зубов, содержащуюся в нем, причем указанная первая композиция для чистки зубов содержит неабразивное отбеливающее вещество и по крайней мере один загуститель; и ! второй отсек, включающий вторую композицию для чистки зубов, содержащуюся в нем, причем указанная вторая композиция отделена от указанной первой композиции, причем указанная вторая композиция содержит абразивное вещество, подходящее для полировки зубов по крайней мере один загуститель, протеолитический фермент и реологический модификатор, который не подвергается разложению посредством указанного протеолитического фермента, причем указанный реологический модификатор присутствует в количестве, эффективном для того, чтобы обеспечить реологическую устойчивость указанной второй композиции для чистки зубов. ! 2. Контейнер по п.1, в котором указанное неабразивное отбеливающее вещество ...

ДВУХФАЗНЫЕ ОТБЕЛИВАЮЩИЕ КОМПОЗИЦИИ ДЛЯ УХОДА ЗА ПОЛОСТЬЮ РТА

Предусмотрены двухфазная отбеливающая композиция для ухода за полостью рта, содержащая гидрофобную фазу и гидрофильную фазу, и способ отбеливания зубов. Гидрофобная фаза содержит источник пероксида водорода; неионногенное поверхностно-активное вещество и донор ацильной группы. Гидрофильная фаза содержит амфотерное поверхностно-активное вещество, фермент, который катализирует реакцию между источником пероксида водорода и донором ацильной группы с образованием надуксусной кислоты. При этом, при комбинировании гидрофобной фазы и гидрофильной фазы получающийся продукт имеет вязкость от около 50000 сП до около 250000 сП. Изобретения позволяют обеспечить увеличение образования отбеливающих агентов за счет более эффективного смешивания фаз. 2 н. и 12 з.п. ф-лы, 4 табл., 2 пр.

СОДЕРЖАЩИЕ ФЕРМЕНТНУЮ СИСТЕМУ КОСМЕТИЧЕСКИЕ КОМПОЗИЦИИ

КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ФЕРМЕНТ РЕПАРАЦИИ ДНК И ЭКСТРАКТ Anogeissus

... 1. Топическая композиция, содержащая по меньшей мере один экстракт из растения рода Anogeissus и по меньшей мере один фермент репарации ДНК.2. Композиция по п.1, для которой экстракт происходит из растения Anogeissus Leiocarpus.3. Композиция по п.1, дополнительно содержащая по меньшей мере один пептид.4. Композиция по п.1, содержащая по меньшей мере один экстракт из Anogeissus Leiocarpus в количестве приблизительно от 0,0001 до 75%; по меньшей мере один фермент репарации ДНК в количестве приблизительно 0,00001 до приблизительно 35%; и по меньшей мере один пептид, имеющий от 2 до 20 аминокислот, в количестве, варьирующем от 0,001 до 20%.5. Композиция по п.4, в которой функцией фермента репарации ДНК является восстановление мутационных повреждений нуклеотидных оснований T-T димера, 8-оксо-дигуанина или 06-метилгуанина.6. Композиция по п.4, в которой фермент репарации ДНК представляет собой одно или более из OGGI, или содержится в лизате Micrococcus, Bifidus, в экстракте Arabidopsis Thaliana ...

ПРИМЕНЕНИЕ ЗЕЛЕНОГО КОФЕ И ПРОБИОТИКА ДЛЯ РЕГУЛИРОВАНИЯ ПИГМЕНТАЦИИ КОЖИ

... 1. Косметическое применение эффективного количества по меньшей мере зеленых кофейных зерен или их экстрактов с микроорганизмами или ферментами, способными гидролизовать хлорогеновые кислоты с образованием феноловых кислот, в качестве активного агента для получения пероральной композиции для лечения и/или предупреждения нарушений пигментации кожи и/или недостатков кожи.2. Применение по п.1, характеризующееся тем, что кожные нарушения представляют собой нарушения, которые наблюдают при меланодермии, веснушках, витилиго, «пегой коже», фенилкетонурии и подобном, и/или старческие пятна.3. Применение по одному из предшествующих пунктов для улучшения тона кожи и/или внешнего вида кожа.4. Применение по п.1 или п.2 для осветления и/или отбеливания тона кожи.5. Применение по п.1 или 2, при котором композиция дополнительно улучшает гидратацию кожи.6. Применение по п.1 или п.2, при котором композиция дополнительно улучшает защитную функцию кожи.7. Применение по п.1 или 2, при котором экстракт получают ...

КОМПОЗИЦИИ ДЛЯ УХОДА ЗА ПОЛОСТЬЮ РТА И СПОСОБЫ ПОВЫШЕНИЯ ИХ СТАБИЛЬНОСТИ

ФАРМАЦЕВТИЧЕСКИЕ ПРИМЕНЕНИЯ ФЕРМЕНТНОЙ КОМПОЗИЦИИ, ВЫДЕЛЕННОЙ ИЗ АНТАРКТИЧЕСКОГО КРИЛЯ

Неиммуногенные ферментные композиции, выделенные из антарктического криля и проявляющие как эндо-, так и экзопептидазную активность, применимы для приготовления лекарственных препаратов и фармацевтических композиций для лечения большого разнообразия заболеваний человека и животных, таких как инфекции, воспаления, раковые заболевания, ВИЧ/СПИД, боль, полипы, бородавки, геморрои, бляшки, морщины, утончение волос, аллергический зуд, спайкообразование, глазные болезни, такие как катаракта, глаукома, и т.д.

КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АКТИВИРУЕМЫЙ ПРОЛИФЕРАТОРАМИ ПЕРОКСИСОМ ГАММА-РЕЦЕПТОР

... 1. Композиция для инъекций, содержащая активируемый пролифераторами пероксисом гамма-рецептор для подкожного введения.2. Композиция по п.1, содержащая, по меньшей мере, один активируемый пролифераторами пероксисом гамма-рецептор, выбранный из группы, включающей эйкозаноиды, в частности простагландины, такие как Δ12-простагландин J2 и 15-деокси-Δ12-простагландин J2, производные тиазолидена, такие как росиглитазон, сиглитазон, троглитазон, энглитазон и пиоглитазон, нестероидные противовоспалительные лекарства, ненасыщенные жирные кислоты, альфа-линолевую кислоту, арахидоновую кислоту, докозагексаеновую кислоту, эйкозапентаеновую кислоту, производные бифенила, производные амида N-(фенилоксазол-4-ил-метоксиметил)-циклогексил-янтарной кислоты и их смеси.3. Композиция по п.1, содержащая ретиноевую кислоту, ретинол, ретиналь и/или рецептор ретиноидов X.4. Композиция по п.1, в которой содержание активируемого пролифераторами пероксисом гамма-рецептора составляет от около 0,00001% по весу до около ...

КОМПОЗИЦИИ ДЛЯ УХОДА ЗА ПОЛОСТЬЮ РТА И СПОСОБЫ ОТБЕЛИВАНИЯ ЗУБОВ

СОДЕРЖАЩАЯ ФЕРМЕНТЫ ДВУХКОМПОНЕНТНАЯ КОМПОЗИЦИЯ ПРОТИВ ЗУБНОГО НАЛЕТА

... 1. Двухкомпонентная композиция средства для чистки зубов, имеющая повышенную антибактериальную эффективность, которая содержит первый и второй компоненты средства для чистки зубов, которые содержат фермент и антибактериальную соль металла в отдельных, орально приемлемых носителях средств для чистки зубов, и в которых анионное поверхностно-активное вещество присутствует только в носителе средства для чистки зубов, содержащем соль металла, причем первый и второй компоненты поддерживаются отдельно друг от друга до распределения и комбинирования для нанесения на зубы, посредством чего получается повышенная антибактериальная эффективность против бактерий ротовой полости, вызывающих образование зубного налета. 2. Композиция по п.1, где фермент представляет собой папаин. 3. Композиция по п.1, где фермент представляет собой глюкоамилазу. 4. Композиция по п.1, где антибактериальная соль металла представляет собой соль двухвалентного олова. 5. Композиция по п.1, где антибактериальная соль металла ...

ZUBEREITUNG ZUR VERLAENGERUNG DER HALTBARKEIT VON LEBENSMITTELN, ARZNEIMITTELN UND KOSMETISCHEN PRODUKTEN.

A compsn. comprising one or more non-enzymatic preservatives (I) and one or more enzymes (II) with N-acetylmuramidase activity in a wt. ratio of 1:100 to 100:1, pref. 1:50 to 50:1. (I) is pref. benzoic acid and/or sorbic acid or their salts. (II) is pref. lysozyme and/or bacteria-lysing enzyme prods. from streptomycetes. The compsn. is added to the prod. to be preserved in an amt. providing 0.01-200 U, esp. 0.1-1000 U of the enzyme with N-acetylmuramidease activity/mg..

HAARFÄRBEMITTEL INDOLIN UND/ODER EINE INDOLINVERBINDUNG UND LACCASE ENTHALTEND

Antimikrobielles Verfahren und Formulierung unter Verwendung von Endoglycosidase vom Typ II und antimikrobielles Mittel

Verfahren und Formulierung unter Verwendung von Endoglycosidase vom Typ II

WASSERLOESLICHE MIKROKAPSELN.

Pseudomonas isomerase enzyme

A Pseudomonas enzyme that catalyses cis/trans isomerisation of unsaturated fatty acids is new, especially an enzyme derived from P. putida DDSM 11306. Also claimed is the gene coding for the enzyme, and a host organism containing the gene.

Präparat zum äusserlichen Gebrauch auf der Haut.

Verfahren zur Herstellung von haltbaren, wasserfreien, hyaluronidasehaltigen Salben

GEBISSREINIGUNGSMITTEL, DIE ENZYME ENTHALTEN UND VERFAHREN ZU DEREN VERWENDUNG.

Topische Hautbehandlungsmittel mit Arginase

Die Erfindung betrifft die Verwendung von Arginase als Komponente zur Verbesserung des Hautzustandes in kosmetischen Zubereitungen zur Pflege der Haut und zur Herstellung dermatologischer Zubereitungen zur topischen Behandlung der Haut. Kosmetische Zubereitungen enthalten bevorzugt 0,001 bis 1000 Einheiten (U) des Enzyms Arginase pro 100 g der Zubereitung und dienen dem Schutz der Haut gegen Trockenheit, Rauhigkeit und Entzündlichkeit.

Oxidatives Färbeverfahren für keratinische Fasern

Die vorliegende Erfindung betrifft Mittel zur Färbung keratinischer Fasern, enthaltend in einem physiologisch akzeptablen Medium mindestens ein Farbstoffvorprodukt sowie mindestens einen Pflanzensaft sowie Mittel zur Färbung keratinischer Fasern, enthaltend in einem physiologisch akzeptablen Medium mindestens ein Farbstoffvorprodukt sowie zumindest die Enzymfraktion sowie die natürlichen Aromastoffe eines Pflanzensaftes. Die erfindungsgemäßen Mittel erfüllen die Anforderungen an Oxidationsmittel für eine oxidative Farbentwicklung in einem hohen Maße.

ZUSAMMENSETZUNG FÜR DIE OXIDATIONSFÄRBUNG VON KERATINISCHEN FASERN

MEHRFACH SUBSTITUIERTE PROTEASEVARIANTEN

Pharmazeutische Zubereitung zur Behandlung der Zahnkaries

OXIDATIONSFÄRBEMITTEL FÜR KERATINFASERN DAS EINE LACCASE ENTHÄLT UND VERFAHREN ZUR FÄRBUNG MIT DIESEM MITTEL

OXIDATIVE ZUSAMMENSETZUNG UND VERWENDUNG ZUM FÄRBEN, ZUR DAUERHAFTEN VERFORMUNG UND ZUM ENTFÄRBEN DER HAAREN

Composition for checking hair loss and for promoting hair growth

The present invention is a further development of Patent Application P 3109420.1-41 (Patent ...). Stabilisers and/or antioxidants are now added, in order to increase the stability, to the composition according to the invention for checking hair loss and for promoting hair growth.

Verwendung von Polyoxyalkylenaminen in enzymhaltigen Wasch- oder Reinigungsmitteln zur Erhöhung der Stabilität von Enzymen

Die Erfindung betrifft die Verwendung von Polyoxyalkylenaminen in enzymhaltigen Wasch- oder Reinigungsmitteln zur Erhöhung der Stabilität von Enzymen sowie ein enzymhaltiges Wasch- oder Reinigungsmittel, insbesondere ein flüssiges Wasch- oder Reinigungsmittel mit verbesserter Enzymstabilität.

ZAHNSCHONENDE,WASSERARME,ZUCKERHALTIGE LEBENSMITTEL UND ZAHNSCHONENDE,WASSERARME PHARMAZEUTISCHE ZUBEREITUNGEN

ABGABESYSTEM FÜR EIN MITTEL GEGEN SCHUPPEN

ZUSAMMENSETZUNGEN ENTHALTEND BETA-GALACTOSIDASE, N-ACETYL-GLUCOSAMINIDASE UND N-ACETYL-GALACTOSAMINIDASE, DIE KEINE PROTEASE ENTHALTEN

OXYDIERUNGSZUSAMMENSETZUNG ZUR ANWENDUNG IN DER BEHANDLUNG VON KERATINISCHEN FASERN

GEBISSREINIGUNGSZUSAMMENSETZUNG

Cosmetic composition

TOOTH PASTE

... 1319423 Toothpastes containing dextranase KAO SOAP CO Ltd 25 June 1971 [26 June 1970] 29929/71 Heading A5B A toothpaste composition comprises dextranase, a foaming agent selected from sodium N-lauroyl sarcosinate, potassium N-2-ethyl laurate sulphoacetamide of the formula and a mixture thereof, and a binder consisting of one or more of sodium alginate, alginic acid propylene glycol ester, carrageenan and gum arabic powder. The composition may comprise from 1 to 1,000 units of dextranase per gram of the composition and the dextranase may be a product of an Aspergillus, Chaetomium, Penicillium, Streptomyces or Sporotichum mould or bacteria. The composition may also comprise a humectant such as glycerol, sorbitol or propylene glycol; a polishing agent such as anhydrous dicalcium phosphate and its dihydrate; sweetening agent, antiseptic such as sodium benzoate or methyl p-hydroxy-benzoate; perfumes and water.

ENZYME-ACTIVATED OXIDATIVE PROCESS FOR COLOURING HAIR

... 1320250 Hair dyeing PROCTER & GAMBLE CO 9 Nov 1971 [9 Nov 1970] 51978/71 Heading D1B Hair is dyed by treating with a solution containing 0.01ppm to 500ppm of an oxidase enzyme selected from laccase, lactate oxidase, glucose oxidase, galactose oxidase, L-2 hydroxyacid oxidase, aldehyde oxidase, monoamine oxidase, and urate oxidase, and from 0.001% to 6% by weight of an aromatic compound which is a primary oxidation dye precursor, (as defined) in the presence of oxygen (e.g. air or H 2 O 2 ) at a pH of 4 to 10 and being free from mixtures of aromatic amines or derivatives thereof with polyhydric phenols or derivatives thereof. Preferably the hair is treated with the dye precursor before the enzyme is added. The solution is preferably aqueous and secondary oxidation dye precursors as defined may also be employed.

Cosmetic composition and use thereof

A skin anti-aging composition

A skin anti-aging composition comprises: (i) a skin cellular synthesis booster; (ii) a skin cellular energizer; (iii) a skin cellular cleanser and (iv) a cosmetically-acceptable excipient. The skin cellular synthesis booster (i) is selected from (a) palmitoyl tripeptide (syn-coll); (b) AC Nano Vesicular System P3; (c) Caprooyl tetrapeptide (chronoline); (d) LOXL inhibitor (Lys'Lastine); (e) Syn-Ake dipeptide. The skin cellular energizer (ii) is selected from (a) EUK-134; (b) Rhodiomax. The skin cellular cleanser (iii) is selected from (a) EUK-134; (b) Photonyl LS; (c) Algesium C; (d) Asorbyl tetraisopalmitate. The composition may further comprise sodium hyaluronate.

Hair nourishing agent and production thereof

The hair nourishing agent is a fermentation product obtained by enzyme action on a substrate comprising vegetable protein and vegetable lipid, the enzymes particularly being a protease and a lipase or the enzymes produced by rice yeast, and contains various amino acids and fatty acids. The substrate may particularly be rice bran, soybean grounds, adzuki grounds or bean-curd refuse. The agent may be used as it is or mixed into a hair lotion, cream, liquid or tonic or into a pomade, shampoo or rinse, together with various other components.

Denture cleansing tablets containing percarbonate and organic peroxyacid bleach precursor

A composition for use in denture cleansing comprises at least one organic peroxyacid bleach precursor, at least one inorganic persalt bleaching agent and a water-soluble or water-dispersable matrix comprising a solid base material which in the presence of water releases carbon dioxide and/or oxygen with effervescence, with the solid base material comprising at least one component phase having an acid or a neutral pH in aqueous medium and at least one inorganic persalt bleaching agent incorporated therein being a percarbonate. Besides excellent cleansing characteristics, the composition exhibits better in-use performance based on the better solubility of percarbonate compared to other inorganic persalt bleaching agents and also confers better environmental performance to the composition.

Oral composition

A fluorine-free local oral composition, for example, a toothpaste comprising a lower alkyl para-hydroxybenzoate and a mesoinositol phosphate ester or its salt is highly antiseptic even in plastic containers.

Improvements in or relating to the production of bactericidal sugar preparations

The tendency of sugar and sugar-containing foods to promote dental caries is diminished by adding to the sugar a bacteriolytic enzyme of animal or vegetable origin, notably the lysozyme of egg white. The lysozyme preparation used may be a solution of egg white or of a salt of the lysozyme, e.g. the hydrochloride, or may be in powder form, e.g. in lactose or dried egg white. Sodium chloride may be present to reinforce the action of the lysozyme. The preparation of lysozyme may be added to beet or cane sugar during the course of its manufacture, sufficient egg white being added for example to confer 10-90 micrograms of lysozyme per gram of sugar.

Cosmetic formulation

ORAL COMPOSITIONS

TOOTH-CLEANING COMPOSITIONS

... 1,270,200. Tooth - cleaning compositions. BLENDAX-WERKE R. SCHNEIDER & CO. 23 Sept., 1970 [25 Sept., 1969], No. 45342/ 70. Heading A5B. Tooth-cleaning compositions contain one or more enzymes and one or more polishing substances, the majority by volume of the polishing substance exhibiting a minimum particle size of 20 microns. The polishing substances may be, for example, calcium phosphate, calcium carbonate and/or silicon dioxide, and the enzymes may be, for example, carbohydrases of proteases such as amylases, dextranases or glucosidases.

Production of Insoluble Proteins

... 1,191,149. Insolubilized enzymes; protein/ polymer derivatives. MONSANTO CO. 23 June, 1967 [24 June, 1966], No. 29188/67. Headings C3H and C3P. A process for the production of a waterinsoluble protein derivative comprises reacting a dissolved protein which comprises free amino groups with a reactive ester derived from a 3-unsubstituted isooxazolium salt and a polymer containing carboxylic acid groups. The polymer may be the protein to be insolubilized, another protein, carboxymethyl cellulose, a copolymer of an olefin and an unsaturated acid, anhydride or salt, or a polymer of an unsaturated acid, e.g. polyacrylic acid or an ethylene/maleic anhydride which is first hydrolysed and then formed into the half sodium salt. Other polymers mentioned are fibres such as wool and cotton which has been oxidized to introduce carboxyl groups. The protein to be insolubilized may be an enzyme, e.g. chymotrypsin.

COMPOSITIONS CONTAINING LACTATE DEHYDROGENASE

STORAGE STABILITY OF AQUEOUS DISPERSIONS OF SPHERULES

Lecithin-based microemulsion containing proteolytic enzymes and method for permanent enzymic depilation.

The invention relates to depilatory containing: proteolytic enzymes solubilized in microemulsions, formed with leithin, aliphatic hydrocarbon, alipathic alchol and buffer solution ph 7 to 9, value corresponding to the ph range near the optimum ph value for the catalytic activity of the proteolytic enzymes, to be applied for permanent enzymic depilation. The application of these preparations will assure, as shown by our experimental studies, more permanent depilation than the one resulting from other depilatory methods. The application of these preparations is suitable for every type of skin (fatty-resistant or dry-sensitive). The present invention introduces the use of microemulsions as a medium for the facilitated penetration of the enzymic activity in the epihelial cells of the skin, as shown by our studies ...

Method and apparatus for continuous flow isoelectric focusing for

Olsztynska 35M7, purifying biological substances.

Lecithin-based microemulsions containing proteolytic enzyme and method for permanent enzymic depilation

Cosmetic

Cosmetic

Method and apparatus for continuous flow isoelectric focusing for purifying biological substances

Lecithin-based microemulsions containing proteolytic enzyme and method for permanent enzymic depilation

Cosmetic

2,6-BETA-D-FRUKTANHYDROLASE ENZYME AND PROCEDURE FOR ITS USE

COSMETIC OR DERMATOLOGI PREPARATION WITH PROTEINS TO THE SKIN CLARIFICATION

CREAM FOR THE TREATMENT OF SUN-DAMAGED SKIN

MEANS AND PROCEDURE FOR COLORING KERATINFASERN

PROCEDURE FOR THE PRODUCTION OF ENZYMHALTIGER, WATER OF POOR ONES, ZUCKERHALTIGER FOOD AND/OR OF PHARMACEUTICAL PREPARATIONS AND ZAHNODER MOUTH PRESERVATIVE AGENTS

SUBTILASEVARIANTEN WITH CHANGE IMMUNOGENITÄT

ORAL COMPOSITION WITH IMPROVED MOUTH HYGIENE CHARACTERISTICS

ENZYMHALTIGE DENTALE TWO-COMPONENT COMPOSITION

COSMETIC NEUROTOXIN COMPOSITIONS WITH A BOTULINUSTOXIN COMPONENT AND A PROCEDURE

ENZYME CONTAINING ORAL COMPOSITION WITH IMPROVED STABILITY

DEPIGMENTATION MEANS WITH A OF ASCOMYCETEN DERIVED ENZYME

PROCEDURE FOR THE PRODUCTION OF ENZYMHALTIGER, WATER OF POOR ONES, ZUCKERHALTIGER FOOD AND/OR OF PHARMACEUTICAL PREPARATIONS AND ZAHNODER MOUTH PRESERVATIVE AGENTS

USE OF A VEGETABLE OIL OR WAX FOR THE STABILIZATION OF ENZYMES

MEANS FOR COLORING KERATINFASERN CONTAINING ALDEHYDE PRE-PRODUCTS, AN ENZYME AND A HYDRAZONE

NICHTVERFÄRBENDE COMPOSITION CONTAINING A PRECURSOR AND A CATALYST FOR OXIDATION REACTIONS

MODIFIED POLYPEPTID

CLEANING AGENT CONTAINING A SPECIAL OXYGENASE

Oral disinfectant, and food additive comprising the disinfectant

Disclosed is a disinfectant which is safe, has few adverse side-effects, can be ingested together with a food or beverage by adding the disinfectant to the food or beverage, shows a bactericidal effect in the oral cavity, and has no problem even when ingested on a daily basis over a long period. Also disclosed is a food additive comprising the disinfectant. Specifically, disclosed is an oral disinfectant for the disinfection of an oral bacterium, which comprises lactoperoxidase, glucose oxidase, glucose and a pH-adjusting component.

Compositions And Methods For Permanent Straightening Of Hair

A hair straightening topical composition comprising transglutaminase and polylysine, which act to form a surface barrier film and moisture shield around human hair. The transglutaminase also contributes to hair straightening. The composition also comprises one or more additional hair straightening agents, other than TGase, that are capable of affecting secondary, tertiary and quaternary protein structures of human hair, preferably sodium metabisulfite and/or tourmaline. The invention includes compositions that may be washed out of the hair after straightening has occurred, and compositions that are intended to remain in the hair for additional or extended benefits. The invention includes methods of using a topical composition that is capable of affecting secondary, tertiary and quaternary protein structures of human hair. Testing indicates that the hair straightening is long term, occurs significantly faster than known commercial hair straightening compositions, and there is significantly less damage to hair compared to known heat and chemical treatments.

Diacylglycerol acyltransferase genes and use thereof

It is an object to provide a novel diacylglycerol acyltransferase. The present invention relates to a diacylglycerol acyltransferase, a polynucleotide encoding the same, and so on. The present invention provides a polynucleotide comprising the nucleotide sequence of, e.g., SEQ ID NO: 1 or 4, a polynucleotide encoding a protein consisting of the amino acid sequence of SEQ ID NO: 2, an expression vector and transformant comprising the polynucleotide, a method for producing a lipid or fatty acid composition using the transformant, or a food, etc. comprising the lipid or fatty acid produced by the method.

Non-aqueous stable composition for delivering substrates for a depilatory product using peracids

Disclosed herein are compositions and methods for delivering substrates for a depilatory product using an enzymatically generated peracid. More specifically, a two component system is provided comprising (a) a first non-aqueous composition comprising a solid source of peroxygen, an ester substrate, and an optional organic cosolvent and (b) an aqueous component having a pH of at least 4 comprising an enzyme catalyst having perhydrolytic activity and a buffer. The perhydrolytic enzyme catalyst may be in the form of a fusion protein comprising a perhydrolytic enzyme coupled through an optional peptide linker to a peptidic component having affinity for hair.

Cross-linked compositions

Improved compositions comprising a cross-linkable protein or polypeptide, and a non-toxic material which induces cross-linking of the cross-linkable protein. The compositions are optionally and preferably prepared in a non-phosphate buffer solvent. Optionally and preferably, the cross-linkable protein includes gelatin and any gelatin variant or variant protein as described herein. Optionally and preferably, the non-toxic material comprises transglutaminase (TG), which may optionally comprise any type of calcium dependent or independent transglutaminase, which may for example optionally be a microbial transglutaminase (mTG).

Stimulation of the synthesis of the activity of an isoform of lysyl oxidase-like loxl for stimulating the formation of elastic fibers

The invention relates to the stimulation of the synthesis and of the activity of an isoform of lysyl oxidase, and more particularly of the LOXL (lysyl oxidase-like) isoform. The invention relates notably to a method of identifying an active principle which stimulates the formation of elastic fibers. The aim of the invention is mainly to provide such a method of identification so as to provide compositions which enable stimulating the formation of elastic fibers.

Oral pharmaceutical formulations for the treatment of human canities

The present application relates generally to oral pharmaceutical formulations for the treatment of human canities.

SKIN ANTIAGING TREATMENT

A method for skin antiaging treatment including administering Botulinum toxin to an area of facial and/or neck skin, combined with the administration of a cosmetic or pharmaceutical composition having a cosmetically or pharmaceutically effective amount of at least one peptide derived from the SNAP-25 protein and/or at least one enkephalin-derived peptide, and at least one cosmetically or pharmaceutically acceptable excipient or adjuvant. 1. A method for skin antiaging treatment comprising:a. The administration of an effective amount of Botulinum toxin to an area of facial and/or neck skin, [{'br': None, 'sub': 1', '2, 'R-AA-R\u2003\u2003(I)'}, 'its stereoisomers, mixtures thereof, and/or its cosmetically or pharmaceutically acceptable salts thereof, in which AA is a sequence selected from the group consisting of SEQ ID No.11, SEQ ID No.4, or a sequence of 7 to 12 adjacent amino acids contained in SEQ ID No.4, wherein said sequence comprises the amino acid sequence of SEQ ID No.11;', 'wherein:', {'sub': 1', '5, 'Ris selected from the group consisting of H, substituted or non-substituted non-cyclic aliphatic group, substituted or non-substituted alicyclyl, substituted or non-substituted heterocyclyl, substituted or non-substituted heteroarylalkyl, substituted or non-substituted aryl, substituted or non-substituted aralkyl and R—C(O)—; and'}, {'sub': 2', '3', '4', '3', '3', '3', '4, 'Ris selected from the group consisting of —NRR, —ORand —SR; where Rand Rare independently selected from the group consisting of H, substituted or non-substituted non-cyclic aliphatic group, substituted or non-substituted alicyclyl, substituted or non-substituted heterocyclyl, substituted or non-substituted heteroarylalkyl, substituted or non-substituted aryl and substituted or non-substituted aralkyl;'}, {'sub': '5', 'wherein Ris selected from the group consisting of H, substituted or non-substituted non-cyclic aliphatic group, substituted or non-substituted alicyclyl, substituted or non- ...

AGENT FOR REDUCING ACETALDEHYDE IN ORAL CAVITY

Disclosed herein is a novel enzymatic agent effective in reducing acetaldehyde in the oral cavity. It has been found that an aldehyde dehydrogenase derived from a microorganism belonging to the genus and a threonine aldolase derived from are effective in reducing low concentrations of acetaldehyde. Therefore, an agent for reducing acetaldehyde in the oral cavity is provided, which contains these enzymes as active ingredients. 1. An agent for reducing acetaldehyde in an oral cavity , comprising an aldehyde dehydrogenase or a threonine aldolase.2Saccharomyces.. The agent for reducing acetaldehyde in an oral cavity according to claim 1 , wherein the aldehyde dehydrogenase is derived from a microorganism belonging to the genus3SaccharomycesSaccharomyces cerevisiae.. The agent for reducing acetaldehyde in an oral cavity according to claim 2 , wherein the microorganism belonging to the genus is4Escherichia coli.. The agent for reducing acetaldehyde in an oral cavity according to claim 1 , wherein the threonine aldolase is derived from5. The agent for reducing acetaldehyde in an oral cavity according to claim 1 , which exhibits degradation activity against acetaldehyde at a substrate concentration of 1 μM to 1 mM.6. The agent for reducing acetaldehyde in an oral cavity according to claim 1 , which exhibits degradation activity against acetaldehyde at a substrate concentration of 1 μM to 100 μM.7. An oral composition comprising the agent for reducing acetaldehyde in an oral cavity according to .8. A method for reducing acetaldehyde in saliva claim 7 , comprising allowing the oral composition according to to act on saliva.9. The method according to claim 8 , which is effective in reducing oral odor.10. The method according to claim 8 , which is effective in preventing cancer whose cause or one of causes is acetaldehyde. The present invention relates to an agent for reducing acetaldehyde in the oral cavity. More specifically, the present invention relates to an agent that ...

USE OF CHICORIC ACID AND LACTIC BACTERIUM IN FOOD SUPPLEMENT FOR REGULATING SKIN PIGMENTATION

The present invention relates generally to the field of cosmetic and/or food supplement. More specifically, the present invention aims to provide the use of at least an ingredient containing chicoric acid and/or derivatives and a micro-organism and/or an enzyme capable of hydrolyzing chicoric acid and/or derivatives thereof to generate tartaric and/or caffeic acid, for improving skin tone and preventing and/or treating hyper-pigmentation of skin and/or skin color imperfections such as age-spots and other skin disorders characterized by abnormal pigments. Also, the present invention aims at providing a skin lightening agent. 1. A method for treating and/or preventing skin pigment disorders and/or skin imperfections comprising administering an oral food supplement comprising an ingredient containing chicoric acid and/or derivatives and a lactic acid bacterium and/or an enzyme capable of hydrolysing chicoric acid to generate tartaric and/or caffeic acid to an individual in need of same.2. Method in accordance with claim 1 , wherein the skin disorders are selected from the group consisting of melasma claim 1 , freckles claim 1 , vitiligo claim 1 , piebaldism claim 1 , phenylketonuria claim 1 , and age spots.3. Method in accordance with for improving skin tone and/or skin complexion.4. A method for lightening and/or whitening skin tone comprising administering an oral food supplement comprising an ingredient containing chicoric acid and/or derivatives and a lactic acid bacterium and/or an enzyme capable of hydrolysing chicoric acid to generate tartaric and/or caffeic acid to an individual in need of same.5. Method in accordance with claim 1 , wherein the composition improves hydration of the skin and/or skin barrier function.6. Method in accordance with claim 1 , wherein the chicoric acid containing ingredient is a natural foodstuff.7. Method in accordance with claim 1 , wherein the composition comprises an enzyme capable of hydrolyzing chicoric acid to generate tartaric ...

Enzymatic peracid generation for use in skin care products

Disclosed herein are compositions and methods to treat skin with a peracid-based benefit agent. The peracid benefit agent can be used for a benefit such as the prevention or treatment of acne, skin whitening, skin bleaching, skin conditioning, reducing the appearance of skin wrinkles, skin rejuvenation, reducing dermal adhesions, and preventing, reducing or eliminating body odors or any combination thereof. The peracid may be enzymatically generated from a carboxylic acid ester substrate using an enzyme having perhydrolytic activity (perhydrolase) in the presence of a source of peroxygen. A fusion protein comprising the perhydrolase coupled to a skin-binding domain, either directly or through an optional linker, may be used to target the perhydrolytic activity to the skin surface.

Method of colouring hair fibres

Hair colourant formulations fall into three main categories designated permanent, semi-permanent and temporary. Permanent hair colourant formulations are oxidative dye systems and generally contain paraphenylene diamine (PPD) and resorcinol, both of which have been shown to cause sensitisation and mutagenicity. Furthermore, severe oxidising conditions are required which in themselves cause skin irritation and sensitization as well as hair fibre damage. The inventive method addresses the aforementioned disadvantages by providing a method of colouring hair fibres, the method comprising the step of applying a hair colour composition, the hair colour composition comprising: (a) (+)-Catechin, (−)-catechin, (+)-epicatechin, (−)-epicatechin or mixtures thereof; (b) A hydrogen peroxide generator or hydrogen peroxide; and (c) A peroxidase and; wherein the composition has a pH of 4.5 to 7.0, preferably less than or equal to 6.0.

Long lasting absorption of flavonoids

The present invention relates to methods for a ong-term and sustained release of flavonoids, in particular rhamnose-containing flavonoids, and for prolonging the uptake of said flavonoids in the gastro-intestinal tract. It further relates to compositions comprising said flavonoid and α-rhamnosidase. It also encompasses compositions comprising hesperidin and hesperetin-7-gluoside.

COSMETIC

A composition is provided that includes a fish spawn protein isolate. A natural product extract is also present that includes unsaturated fatty acids and sterols. An emulsifier is provided to form a mixture of the isolate and the extract. A composition is also provided that includes an egg hatching protein isolate and at least one biocide protective of isolate activity. An emulsifier forms a mixture with the isolate that has an aqueous phase buffered to a pH of between 5.6 and 7.9. A process of producing such a cosmetic has an emulsion or an aqueous phase that is buffered to a pH of between 5.5 and 7.9 prior to the addition of isolate to the emulsion. A process of improving skin appearance is provided that includes the application of the cosmetic to the skin at least three times per week to achieve the improvement of the skin appearance. 1. A cosmetic comprising:a fish spawn protein isolate having an anti-inflammatory effect on mammalian skin;a natural product extract comprising unsaturated fatty acids and sterols, said natural product extract having anti-oxidant activity on the mammalian skin; andan emulsifier or a solubilizer, or a combination thereof forming a mixture of said isolate and said extract.2. The cosmetic of wherein said fish spawn protein isolate is present from 0.00001 to 10 total weight percent.3. The cosmetic of wherein said natural product extract is a plant extract.4. The cosmetic of wherein said unsaturated fatty acids include at least one of an omega-3 claim 1 , omega-6 claim 1 , or omega-9 fatty acid.5. The cosmetic of wherein said sterols include at least one of cholesterol claim 1 , campesterol claim 1 , stigmasterol claim 1 , or sitosterol.6. The cosmetic of further comprising an ascorbic acid or ascorbate salt.7. The cosmetic of wherein said fish spawn protein isolate claim 1 , said natural product extract claim 1 , and said emulsifier are all substantially free of silicone claim 1 , petrolatum claim 1 , synthetic paraben claim 1 , and ...

Hair colorant compositions comprising 2-methoxymethyl-1,4-diaminobenzene and 2,6-diaminopyridine, methods, and kits comprising the compositions

A hair colorant composition comprises 2,6-diaminopyridine coupler in combination with 2-methoxymethyl-1,4-diaminobenzene developer. A kit for coloring hair comprises the hair colorant composition. A method of treating hair comprises applying the hair colorant composition to hair.

HIGH FREQUENCY APPLICATION OF BOTULINUM TOXIN THERAPY

The present invention relates to methods for treating diseases and disorders by administering a composition containing the neurotoxic component of a toxin complex, wherein the composition is devoid of any other protein of the toxin complex and wherein the composition is administered at short intervals and/or in high doses. 1Clostridium botulinumClostridium botulinum. A method of treating a disease or condition caused by or associated with hyperactive cholinergic innervation of muscles or exocrine glands in a patient , the method comprising administering a composition comprising an effective amount of a neurotoxic component of a toxin complex , the composition being devoid of any other protein component of the toxin complex , wherein(a) the patient is a human,(b) the composition is administered by injection, and(c) the composition is administered at an interval of less than three months, the interval comprising a first treatment session and a second treatment session, wherein the amount administered in the second treatment session can be lower, higher or identical to the amount administered in the first treatment.2. The method of claim 1 , wherein the second treatment is performed in order to improve the treatment effect of the first treatment.3. The method of claim 1 , wherein(a) the patient is a patient with a severe movement disorder or severe spasticity; and(b) the effective amount administered exceeds 500 U of neurotoxic component in adults or exceeds 15 U/kg body weight in children.4. The method of claim 3 , wherein the amount which exceeds 500 U is a total amount in adults or exceeds 15 U/kg body weight in children and wherein the amount is administered by(a) injecting a first fraction of this amount during a first treatment session; and(b) injecting the remaining fraction during one or more subsequent treatment session(s), wherein the subsequent treatment session(s) is/are scheduled at least one day after the first treatment session.5Clostridium botulinum. ...

Topical Formulations Comprising DNA Repair Enzymes, and Methods of Use Thereof

Disclosed are methods of decreasing or preventing UV-induced skin damage, comprising the step of applying to an area of skin an effective amount of a topical formulation comprising a photolyase and an endonuclease. In certain embodiments, the formulation is applied before and after UV exposure. 1. A topical formulation , comprising a photolyase; an endonuclease; and a dermatologically acceptable carrier or excipient.2A. nidulans.. The topical formulation of claim 1 , wherein the photolyase is from3M. luteus.. The topical formulation of claim 1 , wherein the endonuclease is from4A. nidulansM. luteus.. The topical formulation of claim 1 , wherein the photolyase is from ; and the endonuclease is from11. A method of decreasing or preventing UV-induced skin damage claim 1 , comprising the step of applying to an area of skin an effective amount of a topical formulation comprising a photolyase; an endonuclease; and a dermatologically acceptable carrier or excipient.12A. nidulans.. The method of claim 11 , wherein the photolyase is from13M. luteus.. The method of claim 11 , wherein the endonuclease is from14A. nidulansM. luteus.. The method of claim 11 , wherein the photolyase is from ; and the endonuclease is from This application claims the benefit of priority to U.S. Provisional Patent Application Ser. No. 61/670,836, filed Jul. 12, 2012.Chronic excessive exposure to ultraviolet radiation (UVR) from sunlight is a causative factor in the development of photoaging and skin malignancies.The harmful effects of UVR from sunlight are currently considered the major environmental risk factor for skin cancer and a complete carcinogen by damaging DNAand suppressing immune responses.The increased risk of cutaneous malignancies linked to chronic UVR exposure has been associated with direct DNA damage,which is mainly represented by the formation of cyclobutane pyrimidine dimers (CPD) that result from the photo [2+2] cycloaddition of the 5,6-double bond of two adjacent pyrimidine ...

Antimicrobial and immunostimulatory system comprising an oxidoreductase enzyme

The present invention relates to an antimicrobial and immunostimulatory system, applications thereof and a process for the production of the antimicrobial and immunostimulatory system. The present invention provides a storage-stable antimicrobial and immunostimulatory system comprising an oxidoreductase enzyme, a substrate for the oxidoreductase enzyme and hydrogen peroxide in an aqueous solution wherein the substrate for the oxidoreductase enzyme is present up to 90% by weight and water is present up to 20% by weight based on the weight of the total composition; the system has a pH from approximately 4 to 8; and the system provides a two-stage hydrogen peroxide release.

COSMETIC KIT, COMPOSITION FOR CHANGING THE FORM OF HAIR FIBRES AND CORRESPONDING APPLICATION METHOD

The present invention relates of a Cosmetic Kit and it composition to do a conformational change of the hairs (curling or straightening) and the respective methods of application, where the composition of the kit is as follows: Cleansing Shampoo, Transformation Cream (Base cream), Enzymatic Gel, Neutralizer, Conditioner and Finishing Fluid, that can be used also in extreme fragile curly hair acting specifically in the conformational change of keratin, mainly on its disulfide bonds where the Transformation Cream (Base cream) should be used together with Enzymatic Gel that have enzymatic activators and the proteolytics enzymes E.C.: 3.4.21.14—CAS# 9014-01-1 and INS1101i (Protemax® 580 L); E.C.: 3.4.21.62—CAS# 9014-01-1 and INS1101i (Prolav® 750); and, E.C: 3.4.24.28—CAS# 76774-43-1 and INS1101i (Protemax® NL600C) that when combined act in a specific and smooth way in the fibers. The invention also presents an application method of the products that compound the Kit (a Protocol). 1. COSMETIC KIT , COMPOSITION FOR CHANGING THE FORM OF HAIR FIBRES AND CORRESPONDING APPLICATION METHOD , characterized by being composed of:Cleanser Shampoo with a pH variant between 7.5 to 8.5, using surfactants like sodium lauryl ether sulphate with a concentration between 20 to 35% by weight, and cocamidopropyl betaine with a concentration between 1 and 10 wt % acid diethanolamide coconut fatty acid concentration from 2.5 to 5.0% by weight addition polymer emulsifying agents and viscosity glycerides of caprylic/capric and tristearate-polyglyceryl-2 concentration between 1.0 and 3.0% by weight;Transformer Cream (cream base) compound of enzyme activating agents, preferably cysteine hydrochloride in a concentration of from 0.01 to 3.0% by weight, plus cysteine concentration of 0.01 to 2.0% by weight;Gel compound of proteolytic enzymes EC: 3.4.21.14—CAS# 9014-01-1 INS1101 I in concentrations from 0.01 to 3% by weight, EC: 3.4.21.62—CAS# 9014-01-1 in a concentration between 0.01 to 3% by weight ...

ORAL CARE COMPOSITION FOR PROMOTING AND MAINTAINING ORAL HEALTH AND METHOD OF FORMING AND USING SAME

An oral care composition, a method of forming the oral care composition, and a method of using the oral care composition are disclosed. The oral care composition includes a plurality of enzymes to prevent formation of and/or facilitate the breakup of biofilm in an oral cavity and a metal ion management system to inhibit growth of gram negative bacteria. 1. An oral care composition comprising:a carrier comprising a solvent;a plurality of enzymes selected from the group consisting of lysozyme, peptizyme, and papain; anda metal ion management formulation comprising one or more compounds selected from the group consisting of sodium EDTA, phytic acid, and lactoferrin.2. The oral composition of claim 1 , further comprising zinc chloride.3. The oral composition of claim 1 , further comprising a demulcent.4. The oral composition of claim 1 , wherein the solvent comprises purified water claim 1 , a thickener claim 1 , and a sweetener.5. The oral composition of claim 1 , wherein the carrier comprises a thickener selected from the group consisting of propanediol claim 1 , carboxymethyl cellulose claim 1 , cellulose gum claim 1 , polyvinyl pyrolidone claim 1 , hydroxylethyl cellulose claim 1 , xanthum gum claim 1 , and combinations thereof.6. The oral composition of claim 1 , wherein the carrier comprises a moisturizing agent.7. A method of using the oral composition of claim 1 , the method comprising the steps of:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'applying the composition of to an oral cavity; and'}discharging the composition.8. The method of claim 7 , wherein the composition is used to freshen breath.9. The method of claim 7 , wherein the composition is used to provide soothing relief.10. The method of claim 7 , wherein the composition is used to provide reduce plaque formation.11. The method of claim 7 , wherein the composition is used to provide reduce tartar formation.12. The method of claim 7 , wherein the composition is used to treat gum disease.13. The ...

COSMETIC

A composition is provided that includes a fish spawn protein isolate. A natural product extract is also present that includes unsaturated fatty acids and sterols. An emulsifier is provided to form a mixture of the isolate and the extract. A composition is also provided that includes an egg hatching protein isolate and at least one biocide protective of isolate activity. An emulsifier forms a mixture with the isolate that has an aqueous phase buffered to a pH of between 5.6 and 7.9. A process of producing such a cosmetic has an emulsion or an aqueous phase that is buffered to a pH of between 5.5 and 7.9 prior to the addition of isolate to the emulsion. A process of improving skin appearance is provided that includes the application of the cosmetic to the skin at least three times per week to achieve the improvement of the skin appearance. 1. A cosmetic comprising:a fish spawn protein isolate present from 0.00001 to 10 total weight percent;a natural product extract present from 0.001 to 10 total weight percent and comprising unsaturated fatty acids and sterols, said natural product extract having anti-oxidant activity on the mammalian skin; andan emulsifier or a solubilizer, or a combination thereof forming a mixture of said isolate and said extract.2. (canceled)3. The cosmetic of wherein said natural product extract is a plant extract.4. The cosmetic of wherein said unsaturated fatty acids include at least one of an omega-3 claim 1 , omega-6 claim 1 , or omega-9 fatty acid.5. The cosmetic of wherein said sterols include at least one of cholesterol claim 1 , campesterol claim 1 , stigmasterol claim 1 , or sitosterol.6. The cosmetic of further comprising an ascorbic acid or ascorbate salt.7. The cosmetic of wherein said fish spawn protein isolate claim 1 , said natural product extract claim 1 , and said emulsifier are all substantially free of silicone claim 1 , petrolatum claim 1 , synthetic paraben claim 1 , and mineral oil.8. The cosmetic of wherein said fish spawn ...

HAIR CLEANSING CONDITIONER

Hair cleansing conditioners which include—in relation to the weight of the total composition— 1. A hair cleansing conditioner comprising—in relation to the weight of the total composition—a) from about 0.0001 to about 10 wt. % of a cationic 3-acrylamidopropyl trimethylammonium salt homopolymer, andb) from about 0.01 to about 20 wt. % of at least one non-ionic surfactant and/or at least one amphoteric surfactant.2. A hair cleansing conditioner according to claim 1 , wherein the 3-acrylamidopropyl trimethylammonium salt homopolymer a) is selected from (3-acrylamidopropyltrimethylammonium chloride homopolymers.3. A hair cleansing conditioner according to claim 1 , comprising at least one non-ionic surfactant (bi).4. A hair cleansing conditioner according to claim 3 , comprising—in relation to its weight—from about 0.01 to about 10 wt. % of the at least one non-ionic surfactant (bi).5. A hair cleansing conditioner according to claim 1 , comprising at least one amphoteric surfactant (bii).6. A hair cleansing conditioner according to claim 5 , comprising—in relation to its weight—from about 0.10 to about 15.00 wt.7. A hair cleansing conditioner according to claim 1 , substantially free from anionic surfactants.8. A hair cleansing conditioner according to claim 1 , which is present in the form of an aerosol mousse in an aerosol container and additionally comprises at least one propellant in a proportion by weight of from about 1.00 to about 50 wt. % in the total weight of the composition.9. A hair cleansing conditioner according to claim 1 , comprising at least one protein hydrolysate in a proportion by weight of from about 0.01 to about 5.00 wt. % in the total weight of the composition.10. A hair cleansing conditioner according to claim 1 , comprisinga. from about 0.0001 to about 10 wt. % of a cationic 3-acrylamidopropyl trimethylammonium salt homopolymer,b. from about 0.01 to about 10 wt. % of at least one non-ionic surfactant (bi), andc. from about 1.00 to about 50 wt. ...

Compositions including bauhinia, methods of making and using the same in skin anti-aging and other skin applications

Topical compositions, packaging systems and methods for improving the appearance of skin or at least one sign of aging in skin including Kachnar are described.

Compositions and Methods for the Delivery of Agents

The present invention relates to methods and compositions for the delivery of cosmetics and medicants. In some embodiments, the invention relates to compositions comprising both hydrophobic and hydrophilic polymers. In preferred embodiments, the invention relates to the delivery of peptides, small molecules and other bioactive compounds using the compositions and methods disclosed herein. 123-. (canceled)24. A method for delivering an active ingredient into the skin: a) providing i) a subject , ii) a solution comprising an active ingredient; iii) a skin patch comprising electro spun hydrophilic fibers; b) pre-wetting the skin of said subject with said solution; and c) administering said skin patch to said subject under conditions such that said active ingredient is delivered into the skin.25. The method of claim 24 , wherein said pre-wetting comprises spraying said solution onto said skin.26. The method of claim 25 , wherein said spraying results in a mist or aerosol.27. A kit claim 25 , comprising a pre-wetting solution claim 25 , and a skin patch claim 25 , said skin patch comprising electro spun hydrophilic fibers.28. The kit of claim 27 , wherein said pre-wetting solution comprises an active ingredient.29. The kit of claim 27 , wherein said patch comprises an active ingredient.30. The kit of claim 27 , further comprising instructions for pre-wetting skin and applying said patch under conditions to form an invisible film that dissolves completely in less than one minute.31. The method of claim 24 , wherein the active ingredient is selected from the group consisting of a cosmetic claim 24 , peptide claim 24 , vitamin claim 24 , organic acid claim 24 , oil claim 24 , drug or medicant.32. The method of claim 31 , wherein said active ingredient is a vitamin.33. The method of claim 32 , wherein said vitamin is selected from the group consisting of vitamin C claim 32 , vitamin A claim 32 , vitamin E claim 32 , vitamin K and vitamin B complex.34. The method of claim 31 ...

COMPOSITIONS AND METHODS TO PREVENT AND TREAT BIOFILMS

Compositions and methods to treat biofilms are disclosed based on the discovery of the role of the disaccharide trehalose in microbial biofilm development. In various embodiments to treat body-borne biofilms systemically and locally, the method includes administering trehalase, the enzyme which degrades trehalose, in combination with other saccharidases for an exposition time sufficient to adequately degrade the biofilm gel matrix at the site of the biofilm. The method also includes administering a combination of other enzymes such as proteolytic, fibrinolytic, and lipolytic enzymes to break down proteins and lipids present in the biofilm, and administering antimicrobials for the specific type(s) of infectious pathogen(s) underlying the biofilm. Additionally, methods are disclosed to address degradation of biofilms on medical device surfaces and biofilms present in industrial settings. 1Staphylococcus aureus{'i': 'S. aureus', 'providing a catheter that has no biofilm growth resulting from bacteria on the catheter; and'}{'i': 'S. aureus', 'adding onto the catheter a composition as a solution comprising trehalase, wherein the trehalase comprises about 0.05%-5% by weight of the composition and the trehalase is derived from a mammalian or plant source wherein biofilm mass and biofilm cell growth by on the catheter is reduced.'}. A method of reducing growth of biofilm mass and biofilm cells on a catheter resulting from bacteria, comprising: This is continuation application of Ser. No. 15/632,618 filed Jun. 26, 2017, which is a continuation-in-part application of Ser. No. 13/481,787 filed May 26, 2012, which is based on provisional application Ser. No. 61/520,654 filed Jun. 13, 2011, the disclosures which are hereby incorporated by reference in their entirety.The present disclosure is generally related to compositions and methods to prevent and treat biofilms.Over the last century, bacterial biofilms have been described as a ubiquitous form of microbial life in various ...

COMPOSITION, CONTAINING RGD MOTIF-CONTAINING PEPTIDE OR FRAGMENT THEREOF, FOR TREATING BURNS AND GLAUCOMA, ALLEVIATING SKIN WRINKLES, AND PROMOTING HAIR GROWTH

The present invention relates to an RGD motif-containing peptide or a fragment thereof, which is used to effectively treat burns and glaucoma, obtain an excellent effect of alleviating skin wrinkles, and is effective in the promotion of hair restoration and hair growth as well as the prevention of hair loss. Therefore, the motif-containing peptide or the fragment thereof can be utilized for a cosmetic composition and a pharmaceutical composition. 18-. (canceled)9. A method for protecting optic nerves , the method comprising:administering to a subject in need thereof an effective amount of a peptide consisting of an amino acid sequence of SEQ ID NO: 1 comprising an RGD motif (Arg-Gly-Asp motif) or its fragment.10. The method according to claim 9 , wherein the fragment is at least one selected from the group consisting of the following fragments:1) a fragment consisting of 5-45 amino acids comprising the RGD motif of SEQ ID NO: 1, optionally with no disulfide bond or 3 or less disulfide bonds between cysteines in the fragment;2) a fragment comprising 30th-38th amino acids in the amino acid sequence of SEQ ID NO: 1, optionally with no disulfide bond or 1 or more disulfide bonds between cysteines in the fragment;3) a fragment comprising 32nd-43rd amino acids in the amino acid sequence of SEQ ID NO: 1, optionally with no disulfide bond or 1 or more disulfide bonds between cysteines in the fragment;4) a fragment comprising 30th-44th amino acids in the amino acid sequence of SEQ ID NO: 1, optionally with no disulfide bond or 1 or more disulfide bonds between cysteines in the fragment;5) a fragment comprising 18th-54th amino acids in the amino acid sequence of SEQ ID NO: 1, optionally with no disulfide bond or 1 or more disulfide bonds between cysteines in the fragment; and6) a fragment comprising 10th-54th amino acids in the amino acid sequence of SEQ ID NO: 1, optionally with no disulfide bond or 1 or more disulfide bonds between cysteines in the fragment.11. The method ...

WOUND HEALING COMPOSITION

The present invention relates to compositions for use in pharmaceutical, cosmetic and cosmeceutical applications, particularly wound healing, including the treatment of lesions and burns. In particular, the present invention relates to compositions comprising platelet enriched plasma (PRP) and stem cell conditioned medium (SC CM) for use in pharmaceutical, cosmetic and cosmeceutical applications such as wound healing. 1. A composition comprising platelet enriched plasma (PRP) and stem cell conditioned medium (SC CM).2. The composition according to claim 1 , wherein said PRP comprises transforming growth factor-β (TGF-β) claim 1 , fibrinogen claim 1 , platelet-derived growth factor (PDGF) claim 1 , epidermal growth factor (EGF) claim 1 , transforming growth factor-α (TGF-α) claim 1 , vascular endothelial growth factor (VEGF) claim 1 , platelet thrombo-plastin claim 1 , thrombospondin claim 1 , coagulation factors claim 1 , calcium claim 1 , serotonin claim 1 , histamine claim 1 , and hydrolytic enzymes.3. The composition according to claim 1 , wherein said SC CM is the medium harvested after the culturing of mesenchymal stem cells.4. The composition according to claim 2 , wherein said SC CM is the medium harvested after the culturing of mesenchymal stem cells.5. The composition according to claim 1 , wherein said SC CM comprises hepatocyte growth factor claim 1 , transforming growth factor β (TGF-β) claim 1 , anti-apoptopic factors claim 1 , keratinocyt growth factor claim 1 , brain-derived neurotrophic factor (BDNF) claim 1 , Flt-3 ligand claim 1 , granulocyte colony stimulating factor (G-CSF) claim 1 , granulocyte/macrophage colony stimulating factor (GM-CSF) claim 1 , macrophage colony stimulating factor (M-CSF) claim 1 , interleukin-6 (IL-6) claim 1 , interleukin-7 (IL-7) claim 1 , interleukin-8 (IL-8) claim 1 , interleukin-11 (IL-11) claim 1 , interleukin leukin-12 (IL-12) claim 1 , leukemia inhibitory factor (LIF) claim 1 , and tumor necrosis factor-alpha (TNF ...

PROPHYLACTIC NORMALIZATION OF CUTANEOUS WOUND REPAIR

The present invention relates to methods of inhibiting scar formation in a skin wound as well as methods of promoting tissue regeneration in a skin wound in a subject in need thereof comprising administering in or near said wound an effective amount of one or more neurotoxins. 1. A method of decreasing scar formation in a skin wound in a subject in need thereof comprising administering to said subject in or near said wound an effective amount of one or more neurotoxins , wherein said amount is sufficient to decrease formation of scar tissue and insufficient to produce muscular paralysis in said wound.2. A method of promoting tissue regeneration in a skin wound in a subject in need thereof comprising administering to said subject in or near said wound an effective amount of one or more neurotoxins , wherein said amount is sufficient to promote regeneration of skin morphology in said wound characteristic of dermis in uninjured skin.3. The method of or wherein said neurotoxin is botulinum neurotoxin or a derivative thereof.4. The method of wherein the botulinum neurotoxin is selected from the group consisting of botulinum neurotoxin A claim 3 , B claim 3 , C claim 3 , D claim 3 , E claim 3 , F claim 3 , and G.5. The method of claim 4 , wherein said botulinum neurotoxin is botulinum neurotoxin A or a derivative thereof.6. The method of wherein the botulinum neurotoxin A is selected from the group consisting of incobotulinumtoxinA claim 5 , onabotulinumtoxinA claim 5 , and abobotulinumtoxinA or a derivative thereof.7. The method of claim 4 , wherein said botulinum neurotoxin is botulinum neurotoxin B or a derivative thereof.8. The method of wherein the botulinum neurotoxin B is rimabotulinumtoxinB or a derivative thereof.9. The method of or wherein said method further comprises administering one or more agents in addition to the neurotoxin in or near said wound.10. The method of wherein said agent is administered prior to administration of said neurotoxin claim 9 , after ...

Cell Penetrating Peptide, Conjugate Comprising Same, and Composition Comprising Conjugate

The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 6, a fragment of any one sequence of SEQ ID NO: 1 to SEQ ID NO: 6, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.

REPAIR OF UV-INDUCED DNA LESIONS

A composition comprising a recombinant enzyme that comprises a fusion of: a cyclobutane pyrimidine dimer photolyase corresponding to an amino acid encoding sequence having at least 85% sequence identity to SEQ ID NO 1, a pyrimidine(6-4)pyrimidone photolyase corresponding to an amino acid encoding sequence having at least 85% sequence identity to SEQ ID NO 2, and a skin penetrating peptide. 115.-. (canceled)16. A composition comprising a recombinant enzyme that comprises a fusion of a cyclobutane pyrimidine dimer photolyase , a pyrimidine(6-4)pyrimidone photolyase and a skin penetrating peptide ,wherein said cyclobutane pyrimidine dimer photolyase corresponds to an amino acid encoding sequence having at least 85% sequence identity to SEQ ID NO 1,wherein said pyrimidine(6-4)pyrimidone photolyase corresponds to an amino acid encoding sequence having at least 85% sequence identity to SEQ ID NO 2.17. The composition of claim 16 , wherein said skin penetrating peptide is encoded by the DNA sequence SEQ ID NO 3.18. The composition of claim 16 , wherein said recombinant enzyme is a deazaflavin photolyase.19. The composition of claim 16 , wherein said recombinant enzyme comprises one or more tag peptides to facilitate purification of the recombinant enzyme.20. The composition of claim 16 , further comprising a carrier and/or an excipient to facilitate uptake of the composition in or on the body.21. The composition of claim 20 , wherein said carrier and/or said excipient comprises an encapsulating material for at least temporarily encapsulating at least said cyclobutane pyrimidine dimer photolyase and said pyrimidine(6-4)pyrimidone photolyase.22. The composition of claim 21 , wherein said carrier and/or said excipient comprises a liposome and/or thermoresponsive polyglycerol particles.23. The composition of claim 16 , further comprising a solubilizer claim 16 , a skin permeation enhancer claim 16 , a preservative claim 16 , a moisturizer claim 16 , a gelling agent claim 16 , ...

Cosmetic Compositions Comprising Cyanodiphenylacrylates

A composition comprising at least one α-cyanodiphenylacrylate and dimethicone/vinyl dimethicone crosspolymer. 1. A topical composition comprising at least one α-cyanodiphenylacrylate and a dimethicone/vinyl dimethicone crosspolymer.3. The composition of wherein Rand Rare each independently C claim 4 , and any non-alkoxy radical Ror Ris hydrogen; and Ris a straight of branched chain Calkyl.4. The composition of wherein R1 and R2 are each independently methoxy claim 5 , and any non-methoxy Ror Ris hydrogen; and Ris a Calkyl.5. The composition of wherein the α-cyanodiphenylacrylate is ethylhexylmethoxycrylene.6. The composition of additionally comprising a chemical or physical sunscreen.7. The composition of wherein the physical sunscreen is zinc oxide claim 1 , titanium dioxide claim 1 , or mixtures thereof.8. The composition of wherein the chemical sunscreen is selected from the group consisting of Avobenzone claim 6 , octisalate claim 6 , terephthalylidene dicamphor sulfonic acid claim 6 , Octocrylene claim 6 , 4-methylbenzylidene camphor claim 6 , Cinoxate claim 6 , Benzophenone-3 claim 6 , octylmethoxycinnamate claim 6 , and mixtures thereof.9. The composition of in the form of an emulsion.10. The composition of wherein the emulsion is a water in oil emulsion.11. The composition of wherein the emulsion is an oil in water emulsion.12. The composition of additionally comprising a DNA repair enzyme.13. The composition of additionally comprising an oxyalkylenated organosiloxane emulsifier.14. The composition of wherein the emulsifier is dimethicone copolyol claim 13 , alkyl dimethicone copolyol claim 13 , or mixtures thereof.15. A method for improving dispersion of ingredients in a cosmetic composition comprising formulating the composition to contain at least one α-cyanodiphenyl acrylate and a dimethicone/vinyl dimethicone crosspolymer. The invention is in the field of compositions for application to keratinous surfaces for coloring, conditioning, or treating the ...

KITS AND METHODS OF USING HYALURONIDASE TO MODIFY POLYSACCHARIDE FILLERS AND DELIVERY SYSTEMS

Embodiments of the present invention are directed to kits, compositions and methods for modifying and altering poly-saccharide fillers and drug delivery systems with the application of hyaluronidase 1. A method of altering or modifying a mass comprising a polysaccharide comprising the steps of:a. administering an effective amount of a hyaluronidase to the mass.2. The method of claim 1 , wherein said polysaccharide has one or more sugars selected from the group consisting of D-galactose and 3 claim 1 , 6-anhydro-L-galactopyranose.3. The method of claim 1 , wherein said hyaluronidase is a recombinant enzyme.4. The method of claim 1 , wherein said polysaccharide is an agarose.5. The method of claim 1 , wherein said mass is a dermal filler.6. The method of claim 1 , wherein said mass is a delivery vehicle for one or more drugs.7. The method of claim 1 , wherein said hyaluronidase is administered to the mass in vivo.8. The method of claim 1 , wherein said hyaluronidase is administered with the polysaccharide.9. A drug delivery system comprising a polysaccharide and hyaluronidase held in a vessel for reconstitution.10. The drug delivery system of further comprising drug.11. A kit for performing dermal filling procedures comprising:a. a polysaccharide for forming a mass in the body of an animal; andb. an hyaluronidase for altering said polysaccharide, for administration with said polysaccharide or to said mass held in the body to effect a modification of said mass.12. The kit of wherein said polysaccharide has one or more sugars selected from the group consisting of D-galactose and 3 claim 11 , 6-anhydro-L-galactopyranose.13. The kit of wherein said hyaluronidase is recombinant.14. The kit of wherein said polysaccharide is an agarose.15. A dermal filler formulation comprising agarose and neoagarosehexaose.16. A method of performing dermal filling comprising the step of administering the dermal filler formulation of . This application claims priority to U.S. Provisional ...

IMPROVED DELIVERY OF LARGE AGENTS

Methods, compositions, and devices for enhancing transdermal delivery and/or bioavailability of large agents. 1. A method comprising a step of:{'sup': '2', 'applying an emulsion composition comprising a large agent having a molecular weight of 100,000 Da or greater to a site in combination with microneedle skin conditioning (MSC) of the site with a microneedle array having a microneedle density within a range of about 2 to about 50 microneedles/cm.'}2. The method of claim 1 , wherein the microneedle density within a range of about 2 to about 10 microneedles/cm.3. The method of claim 1 , wherein the microneedle density within a range of about 2 to about 35 microneedles/cm.4. The method of claim 1 , wherein the composition comprising a large agent comprises a nanoemulsion comprising the large agent.5. The method of claim 1 , wherein the composition comprising a large agent comprises a macroemulsion comprising the large agent.6. The method of any one of - claim 1 , further comprising the administration of a non-irritating penetration enhancing agent.7. The method of claim 6 , wherein the non-irritating penetration enhancing agent is selected from carrier peptides and co-peptides.8. The method of any one of - claim 6 , wherein the non-irritating penetration enhancing agent is selected from a cationic peptide and a positively charged carrier with the sequence RKKRRQRRRG-(K)-GRKKRRQRRR.9. The method of any one of - claim 6 , wherein the MSC of the site is performed before applying the composition comprising a large agent to the site.10. The method of claim any one of - claim 6 , wherein the MSC of the site is performed after applying the composition comprising a large agent to the site.11. The method of claim any one of - claim 6 , wherein the MSC of the site and applying the composition comprising a large agent to the site occur at substantially the same time.12. The method of any one of - claim 6 , wherein the large agent is a botulinum toxin.13. The method of claim 12 ...

Method and Composition for Oral Health Care Treatment

A method for oral health treatment of a subject using a composition having an anti-oxidant enzyme, an anti-inflammatory agent, and a pharmaceutically acceptable buffer. In certain embodiments, the compositions are administered to the subject in conjunction with teeth whitening, oral surge oral pathology treatment, endodontic therapy, periodontal therapy, dental restoration, preventative tooth cleaning, or subsequent to a pro-oxidant. 1. A method for educing an elevated free radical concentration in an oral cavity of a subject , comprising administering to the subject's oral cavity a composition comprising (a) an effective amount of an anti-oxidant enzyme , wherein the anti-oxidant enzyme is catalase; (b) an effective amount of an anti-inflammatory agent; and (c) a pharmaceutically acceptable buffer , whereby an elevated free radical concentration in the oral cavity of the subject is reduced.2. The method of claim 1 , wherein the composition is provided to the subject in conjunction with a dental procedure.3. The method of claim 2 , wherein the dental procedure is selected from the group consisting of teeth whitening claim 2 , oral surgery claim 2 , oral pathology treatment claim 2 , endodontic therapy claim 2 , periodontal therapy claim 2 , dental restoration claim 2 , general preventative tooth cleaning claim 2 , a pro-oxidant treatment claim 2 , internal or external dental bleaching claim 2 , tooth extraction claim 2 , hard or soft tissue surgery claim 2 , root canal therapy claim 2 , apical surgery claim 2 , debridement claim 2 , scaling claim 2 , root planing claim 2 , composite or bonding procedure claim 2 , and a prophylactic procedure.4. The method of claim 1 , wherein the anti-inflammatory agent is selected from the group consisting of an extract of pomegranate claim 1 , cranberry claim 1 , acai berry claim 1 , rooibos claim 1 , green tea claim 1 , avocado claim 1 , and mixtures thereof.5. The method of claim 1 , wherein the composition further comprises a ...

BOTULINUM TOXIN PREFILLED CONTAINER

The present invention relates to a prefilled plastic container, such as a plastic syringe, comprising an aqueous botulinum toxin formulation. The aqueous botulinum toxin formulation in the prefilled plastic container is stable for a prolonged time period. Furthermore, the present invention relates to a kit comprising the prefilled plastic container, and to the use of the prefilled plastic container for therapeutic and cosmetic purposes. 1. A prefilled plastic container comprising an aqueous botulinum toxin formulation , wherein the toxin activity is not reduced by more than 25% , relative to the initial toxin activity , upon storage of the prefilled container for 12 months at 5° C. or 3 months at 25° C.2. The prefilled plastic container of claim 1 , wherein the number of sub-visible particles of equal to or greater than 10 μm is below 1000/ml during storage for 6 to 24 months at 2° C. to 25° C.3. The prefilled plastic container of claim 1 , wherein the pH value is not increased or decreased by more than 10% claim 1 , relative to the initial pH value claim 1 , during storage of the prefilled container for 6 to 24 months at 2° C. to 25° C. claim 1 , or wherein the pH of the aqueous botulinum toxin formulation during storage is maintained in the range of 6.1 to 7.3 claim 1 , or both.4. The prefilled plastic container of claim 1 , wherein the botulinum toxin is present in the aqueous formulation at a concentration of 10 U/ml to 1000 U/ml.5. The prefilled plastic container of claim 1 , wherein the aqueous botulinum toxin formulation in the prefilled container does not contain a buffer.6. The prefilled plastic container of claim 1 , wherein the container is (i) a syringe claim 1 , (ii) a vial claim 1 , (iii) a carpule claim 1 , or (iv) an ampoule.7. The prefilled plastic container in the form of a prefilled plastic syringe of comprising:(a) a plastic syringe barrel including a proximal end and a distal end, and a generally cylindrical wall extending therebetween and ...

SENSATION-IMPROVING AGENT

An object of the present invention is to provide a safety sensation-improving agent that can improve dulled peripheral sensations through daily ingestion or application to the skin. Another object of the present invention is to provide a sensation-improving food, beverage, feed, or cosmetics that can improve dulled peripheral sensations through oral ingestion or application to the skin. A sensation-improving agent containing a milk-derived protein and/or a hydrolysate therefrom as an active ingredient is provided. The milk-derived protein and/or the hydrolysate therefrom can be orally ingested or applied direct to the skin to improve dulled sensations, particularly peripheral sensations, and be formed into a sensation-improving food, beverage, feed, or cosmetics. 1. A method for improving dulled peripheral sensation in a mammal , comprising orally administering a milk-derived protein and/or a hydrolysate therefrom to a mammal , or applying a milk-derived protein and/or a hydrolysate therefrom to the skin of the mammal.2. The method according to claim 1 , wherein the mammal is a human claim 1 , and the milk-derived protein and/or hydrolysate therefrom is orally administered at a dose of 10 mg or more per day for an adult human.3. The method according to claim 2 , wherein the milk-derived protein and/or the hydrolysate therefrom is orally administered at a dose of 10-20 mg per day for an adult human.4. The method according to claim 1 , wherein the milk-derived protein is at least one selected from lactoperoxidase claim 1 , lactoferrin claim 1 , cystatin claim 1 , and angiogenin.5. The method according to claim 1 , wherein the hydrolysate from the milk-derived protein is produced through hydrolysis of the milk-derived protein with a protease.6. The method according to claim 5 , wherein the protease is at least one selected from the group consisting of pepsin claim 5 , trypsin claim 5 , chymotrypsin claim 5 , and pancreatin.7. The method according to claim 1 , ...

METHOD FOR NON-SURGICAL FACIAL REJUVENATION

A method for non-surgical rejuvenation of facial skin to correct both Type 1 aging changes in the epidermis layer of the skin causing visual changes in the skin and Type 2 aging changes in the dermis layer of the skin causing damage to supportive elements of the skin. The method includes the steps of exfoliation of the facial skin, stimulation of new dermal collagen deposition, removal of at least one of pigment and superficial blood vessels, relaxation of facial expression muscles, filling of soft tissue defects including at least one of deep facial lines and contour deformities, and tightening of the facial skin, and the steps of the method are applied according to a selected one of a plurality of age determined regimens. 1. A method for non-surgical rejuvenation of facial skin , comprising the steps of:exfoliation of the facial skin,stimulation of new dermal collagen deposition,removal of at least one of pigment and superficial blood vessels,relaxation of facial expression muscles,filling of soft tissue defects including at least one of deep facial lines and contour deformities, andtightening of the facial skin.2. The method of for non-surgical rejuvenation of facial skin claim 1 , further including: correcting of at least one of atrophy of subcutaneous fat and loss of bone, and', 'at least one of a dietary regime, an exercise regime and an administering of vitamin supplements., 'at least one of'}3. The method of for non-surgical rejuvenation of facial skin wherein the step of exfoliation of the facial skin includes: application of an emollient, and', 'mechanical exfoliation, and', 'laser peeling., 'at least one of'}4. The method of for non-surgical rejuvenation of facial skin wherein the step of stimulation of new dermal collagen deposition includes: application of an anti-oxident agent,', 'application of collagen stimulating agent, and', 'laser light therapy., 'at least one of'}5. The method of for non-surgical rejuvenation of facial skin wherein the step of ...

RECOMBINANT PROTEINS COMPRISING BOTULINUM TOXIN AND CELL PENETRATING PEPTIDE AND COSMETIC COMPOSITION COMPRISING THEREOF

Disclosed herein is a recombinant protein including botulinum toxin and cell penetrating peptides and cosmetic composition. The cell penetrating peptide according to the present disclosure may be actively used as a topical agent for various disease treatment, aesthetic, or cosmetic purposes, especially for a cosmetic composition, by securing better convenience as well as maximizing the intrinsic in vivo efficacy of the botulinum toxin through the cell penetrating recombinant proteins that combines the botulinum toxin and a cell penetrating peptide by making skin penetration and/or cell penetration for botulinum toxin more efficient. 1. Recombinant proteins , comprising:Botulinum toxin; andCell penetrating botulinum toxin recombinant proteins comprising cell penetrating peptides.The cell penetrating peptide is a peptide that is capable of mediating the transport of an active molecule into a cell and is a cell penetrating botulinum toxin recombinant protein, characterized in that it consists of one amino acid sequence type selected from the group consisting of sequence number 1 to sequence number 13.2. The recombinant proteins of claim 1 , wherein the active molecule is a cell penetrating botulinum toxin recombinant protein claim 1 , characterized in that it consists of one or more selected from the group consisting of growth factors claim 1 , enzymes claim 1 , transcription factors claim 1 , toxins claim 1 , antigenic peptides claim 1 , antibodies claim 1 , antibody fragments claim 1 , nucleic acids claim 1 , coding nucleic acid sequences claim 1 , mRNAs claim 1 , antisense RNA molecules claim 1 , microRNAs claim 1 , siRNAs claim 1 , carbohydrates claim 1 , lipids claim 1 , and glycolipids.3. The recombinant proteins of claim 1 , wherein the botulinum toxin is a cell penetrating botulinum toxin recombinant protein claim 1 , characterized in that it consists of one type selected from the group consisting of serotypes A claim 1 , B claim 1 , C claim 1 , D claim 1 , E ...

Preparation of Stabilized Catalase Enzymes with a Surfactant

There is provided a method of producing a stabilized microcrystalline cellulose powder containing catalase enzyme. In the method, cellulose is thoroughly mixed with phosphate borate and catalase, rinsed with water and a surfactant added. The stabilized powder may be mixed with various skin solutions (lotions, ointments and the like). The catalase enzyme can catalyze the reaction of peroxide to oxygen. 13-. (canceled)4. A microcrystalline cellulose substrate adsorbed with a catalase enzyme and further comprising a surfactant , wherein the catalase enzyme exhibits a decreased loss in catalase activity compared to a catalase enzyme not adsorbed on the microcrystalline cellulose substrate with the surfactant , wherein the catalase enzyme adsorbed on the microcrystalline cellulose substrate with the surfactant has an activity at 25° C. between 500 IU/g and 1 ,000 ,000 IU/g , wherein the catalase enzyme adsorbed on the microcrystalline cellulose substrate with the surfactant is stable for up to 12 weeks at 35° C. after thermal cycling at 40° C. for 72 hours and 55° C. for 6 hours.5. A skin hydrator lotion comprising lotion and the microcrystalline cellulose substrate of .6. The microcrystalline cellulose substrate of claim 4 , wherein the catalase enzyme adsorbed on the microcrystalline cellulose substrate has a molecular weight of less than 500 claim 4 ,000 Daltons.7. The microcrystalline cellulose substrate of claim 4 , wherein the catalase enzyme adsorbed on the microcrystalline cellulose substrate includes manganese atoms.8. The microcrystalline cellulose substrate of claim 4 , wherein said catalase enzyme adsorbed on the microcrystalline cellulose substrate is obtained from fungus.9Aspergillus niger.. The microcrystalline cellulose substrate of claim 8 , wherein the fungus is10. The microcrystalline cellulose substrate of claim 4 , wherein the surfactant comprises Tween 20.11. The microcrystalline cellulose substrate of claim 4 , wherein the catalase enzyme adsorbed ...

Topical Skin Care Composition For Night Use

Topical skin care composition for night use containing a combination of stabilized anti-oxidants, oat derived avenanthramides, retinol-like compounds and biofunctional peptides and other optional ingredients for topical application for the treatment and prevention of skin damage due to environmental factors. 1. A topical skin care composition comprising:(a) a meroterpene;(b) a complex including bidens pilosa extract, elaeis guineesis oil, gossypium herbaceum seed oil, and linum usitatissimum seed oil;(c) myristoyl tripeptide-31;(d) an oat avenanthramide extract;(e) an anti-inflammatory peptide;(f) a soy based active complex;(g) an argirilene-like peptide;(h) hyaluronic acid;(j) a water soluble enzyme;(k) an aloe barbadensis leaf extract;(l) oat β-glucan;(m) a source of allantoin;(n) a source of moisturizing saccharide complex;(o) a complex including rice extract, rosemary extract, sunflower extract and tocopherol;(p) an ascorbic acid source;(q) daikon radish oil; and(r) a cosmetically acceptable carrier.2. The topical skin care composition of claim 1 , wherein the aloe barbadensis extract is present in the amount of 0.01% to 0.50% by weight.3. The topical skin care composition of claim 1 , wherein the source of ascorbic acid is tetrahexydecyl ascorbate.4. The topical skin care composition of claim 1 , wherein the source of ascorbic acid is present in the amount of 0.01% to 10% by weight.5. The topical skin care composition of claim 1 , wherein the meteropene is bakuchiol.6. The topical skin care composition of claim 1 , wherein the daikon radish oil is present in the amount of 0.1% to 10.0% by weight.7. The topical skin care composition of claim 1 , wherein the moisturizing saccharide complex is an apple extract.8. The topical skin care composition of claim 1 , wherein the water soluble enzyme is derived from mushroom.9. The topical skin care composition of claim 1 , wherein the oat β-glucan is colloidal oatmeal.10. The topical skin care composition of claim 1 , ...

Preparation of Stabilized Catalase Enzymes Using Polyvinyl Alcohol

There is provided a method of producing a stabilized catalase enzyme. In the method, a substrate is thoroughly mixed with phosphate borate and catalase, rinsed with water and the solids dried. The dried solid may be mixed with polyvinyl alcohol and dried for further stabilization. The stabilized powder may be mixed with various skin solutions (lotions, ointments and the like). The catalase enzyme can catalyze the reaction of peroxide to oxygen. 15-. (canceled)6. A microcrystalline cellulose adsorbed with a catalase enzyme and further comprising polyvinyl alcohol , wherein the catalase enzyme adsorbed on the microcrystalline cellulose with the polyvinyl alcohol exhibits a decreased loss in catalase activity compared to a catalase enzyme not adsorbed on the substrate with the polyvinyl alcohol , wherein the catalase enzyme adsorbed on the microcrystalline cellulose with the polyvinyl alcohol has an activity at 25° C. between 500 IU/g , and 1 ,000 ,000 IU/g , and wherein the catalase enzyme adsorbed on the microcrystalline cellulose with the polyvinyl alcohol is stable for up to 16 weeks at 35° C. after thermal cycling at 40° C. for 72 hours and 55° C. for 6 hours.7. A skin hydrator lotion comprising lotion and the microcrystalline cellulose of .8. (canceled)9. The microcrystalline cellulose of claim 6 , wherein the ratio of the microcrystalline cellulose to the catalase enzyme adsorbed on the microcrystalline cellulose is between 1 and 10.10. The microcrystalline cellulose of claim 6 , wherein the catalase enzyme adsorbed on the microcrystalline cellulose with the polyvinyl alcohol includes manganese atoms.11. The microcrystalline cellulose of claim 6 , wherein the catalase enzyme adsorbed on the microcrystalline cellulose with the polyvinyl alcohol has a molecular weight of less than 500 claim 6 ,000 Daltons.12. The microcrystalline cellulose of claim 6 , wherein the catalase enzyme adsorbed on the microcrystalline cellulose with the polyvinyl alcohol is derived from ...

Methods And Compositions For Improving The Appearance Of Skin

A method for stimulating collagen synthesis in aging skin cells in need of treatment by stimulating SIRT1, SIRT3, and SIRT6 and a method for preparing a topical composition for stimulating SIRT1, SIRT3, and SIRT6 in skin cells. 1LaminariaNarcissus. A method for stimulating collagen synthesis in skin cells in need of such treatment by topically applying a composition comprising at least one extract from genus , at least one extract from the genus , and at least one peptide that stimulates SIRT6 activity.2. The method of wherein the stimulation of collagen synthesis causes a reduction in skin laxity claim 1 , a reduction in the appearance of lines or wrinkles claim 1 , or both.3. The method of wherein the topical composition is applied once or twice per day.4. The method of wherein the topical composition is applied before a period of sustained rest.5Laminaria. The method of wherein the extract from the genus stimulates SIRT3 activity in skin cells.6LaminariaLaminaria saccharina.. The method of wherein the extract from the genus is7Narcissus. The method of wherein the extract from the genus stimulates SIRT1 activity in skin cells.8NarcissusNarcissus tazetta. The method of wherein the extract from the genus is extract from the bulb in its dormant phase of growth.9. The method of wherein the peptide has the formula (I):{'br': None, 'sub': 1', 'n', '1', '2', '3', '4', '5', '6', 'p', '2, 'R-(AA)-X—X—X—X—X—X-(AA)-R, in which'}{'sub': '1', 'Xis glycine or threonine or histidine;'}{'sub': '2', 'Xis alanine or glutamine or glycine;'}{'sub': '3', 'Xis glycine or asparagine or serine;'}{'sub': '4', 'Xis valine or isoleucine or leucine;'}{'sub': '5', 'Xis serine or aspartic acid or phenylalanine;'}{'sub': '6', 'claim-text': [{'sub': 1', '2', '3, 'when Xis glycine, then Xis alanine and Xis glycine;'}, {'sub': 1', '3, 'when Xis threonine, then Xis asparagine;'}, {'sub': 1', '2, 'when Xis histidine, then Xis glycine;'}, 'AA represents any amino acid and n and p are integers between ...

Cosmetic

A composition is provided that includes a fish spawn protein isolate. A natural product extract is also present that includes unsaturated fatty acids and sterols. An emulsifier is provided to form a mixture of the isolate and the extract. A composition is also provided that includes an egg hatching protein isolate and at least one biocide protective of isolate activity. An emulsifier forms a mixture with the isolate that has an aqueous phase buffered to a pH of between 5.6 and 7.9. A process of producing such a cosmetic has an emulsion or an aqueous phase that is buffered to a pH of between 5.5 and 7.9 prior to the addition of isolate to the emulsion. A process of improving skin appearance is provided that includes the application of the cosmetic to the skin at least three times per week to achieve the improvement of the skin appearance.

Method and Compositions for Treating Dermal Papilla Cells Associated with Keratin Fibers

A composition for topical application to dermal papilla cells associated with keratin fibers from scalp, eyelashes or eyebrows comprising at least one OGG1 DNA repair enzyme, and method for treating dermal papilla cells associated with keratin fibers to inhibit oxidative damage, stimulate melanin synthesis, and reduce apoptosis. 1. A composition for topical application to dermal papilla cells associated with keratin fibers from scalp , eyelashes or eyebrows comprising at least one OGG1 DNA repair enzyme.2. The composition of where the OGG1 DNA repair enzyme is present in an amount ranging from 0.00001 to 5%.3Bifido. The composition of further comprising at least one inactivated bacterial lysate of bacterium.4. The composition of which is a rinse off composition or a leave on composition.5. The composition of which is a shampoo claim 1 , hair conditioner claim 1 , scalp treatment composition claim 1 , lash treatment composition claim 1 , brow treatment composition claim 1 , mascara claim 1 , or brow color.6Arabidopsis thaliana. The composition of wherein the DNA repair enzyme is extract.7. The invention is directed to a method for inhibiting oxidative damage to dermal papilla cells associated with keratin fibers and exposed to reactive oxygen species comprising treating the cells with an effective amount of a DNA repair enzyme.8. The method of wherein the keratin fibers are scalp hair claim 7 , eyelashes claim 7 , or eyebrows.9. The method of wherein the DNA repair enzyme is OGG1.10. The method of wherein the DNA repair enzyme is applied in the form of a rinse off composition or a leave on composition.11. The method of wherein the rinse off composition is a shampoo or hair conditioner.12. The method of wherein the composition is a leave on composition.13. The method of wherein the leave on composition is a hair treatment composition claim 11 , a lash treatment claim 11 , a brow treatment claim 11 , a lash color claim 11 , or a brow color.14. A method for stimulating ...

ORAL CARE COMPOSITION

The present invention relates an oral care composition, comprising one or more functional agents selected from a group consisting of a whitening agent, a re-mineralizing agent, an anti-plaque agent, an anti-gingivitis agent, a detoxifying agent and its combinations. The composition further comprises a probiotic blend consisting of beneficial oral bacterial population and at least one essential oil comprising antimicrobial activity. 1. An oral care composition , comprising:One or more functional agents selected from a group consisting of a whitening agent, a re-mineralizing agent, an anti-plaque agent, an anti-gingivitis agent, a detoxifying agent and any of its combinations;a probiotic blend comprising beneficial oral bacteria; andat least one essential oil comprising antimicrobial activity.2. The composition of claim 1 , further comprises a nutritional supplement claim 1 , wherein the nutritional supplement comprises Norwegian kelp.3L. rueteri, L. fermentum, L. rhamnosus, S. thermophilus, S. salivarius. The composition of claim 1 , wherein the probiotic blend comprises of bacteria selected from a group consisting of and its combinations thereof.4. The composition of claim 1 , wherein the essential oil is selected from a group consisting of clove oil claim 1 , cinnamon oil claim 1 , oregano oil claim 1 , peppermint oil claim 1 , sesame oil and its combinations thereof.5. The composition of claim 1 , wherein the anti-plaque agent and the anti-gingivitis agent comprises enzymes to digest plaque and act against gingivitis.6. The composition of claim 5 , wherein the enzymes are selected from a group consisting of bromelain claim 5 , papain and its combinations thereof.7. The composition of claim 1 , wherein the whitening agent is selected from a group consisting of sodium bicarbonate claim 1 , calcium peroxide claim 1 , sodium phosphate claim 1 , Himalayan pink salt and its combinations thereof.8. The composition of claim 1 , wherein the re-mineralizing agent is ...

COSMETIC NEUROTOXIN COMPOSITIONS AND METHODS

Cosmetic compositions include a Clostridial neurotoxin component and a microsphere component. In certain compositions, the composition includes a botulinum toxin and a plurality of swellable microspheres. The compositions are administered to individuals, by injection and the like, to treat a cosmetic defect of deficiency. 1. A composition useful for treating a cosmetic defect in an individual , comprising a botulinum toxin component; and a microsphere component comprising a plurality of swellable microspheres.2. The composition of claim 1 , wherein the botulinum toxin component comprises a botulinum toxin selected from the group consisting of botulinum toxins types A claim 1 , B claim 1 , C claim 1 , D claim 1 , E claim 1 , F claim 1 , G claim 1 , and mixtures thereof.3. The composition of claim 1 , wherein the botulinum toxin component comprises only botulinum toxin type A.4. The composition of claim 1 , wherein the botulinum toxin component comprises an amount of botulinum toxin in a range from about 10 units to about 2 claim 1 ,000 units of a botulinum toxin type A.5. The composition of claim 1 , wherein the botulinum toxin component comprises an amount of botulinum toxin in a range from about 100 units to about 30 claim 1 ,000 units of a botulinum toxin type B.6. The composition of being substantially free of a botulinum toxoid.7. The composition of claim 1 , wherein the microsphere component has an average microsphere diameter claim 1 , and the average microsphere diameter after administration to the individual is between about one to about four times greater than the average microsphere diameter before administration.8. The composition of claim 1 , wherein the micropsheres comprise an agent selected from the group consisting of radio-pacifying agents claim 1 , contrast agents claim 1 , targeting agents claim 1 , and mixtures thereof.9. The composition of claim 1 , further comprising a carrier component.10. The composition of claim 9 , wherein the carrier ...

TRANSPORT PROTEIN WHICH IS USED TO INTRODUCE CHEMICAL COMPOUNDS INTO NERVE CELLS

The invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by . The protein binds specifically to nerve cells with a higher affinity as the native neurotoxin. The invention also relates to a method for the production of transport protein, the nucleic acids coding for the transport protein, the transport protein containing pharmaceutical and cosmetic compositions and use thereof. 1Clostridium botulinumClostridium. A transport protein , obtained by modification of the heavy chain of a type A (BoNT/A) , said heavy chain comprising a H-fragment and a H-fragment , wherein said H-fragment includes a H-fragment and a H-fragment , wherein the H-fragment of the BoNT/A heavy chain is substituted by the H-fragment of a different neurotoxin type , wherein said transport protein binds to a motor neuron.2. The transport protein according to claim 1 , wherein the protein binds specifically to motor neurons and enters the cells by endocytosis.3. The transport protein according to claim 1 , wherein the protein binds specifically to complex gangliosides of cholinergic motor neurons claim 1 , localised in the plasma membrane.4. The transport protein according to claim 3 , wherein the complex gangliosides of cholinergic motor neurons is GT1b.5Clostridium. The transport protein according to claim 3 , wherein the H-fragment of the different neurotoxin type includes the binding domain of the transport protein claim 3 , and wherein said fragment includes substitutions and/or deletions of amino acids.6Clostridium botulinum. The transport protein according to claim 1 , wherein the protein exhibits a binding affinity at least 15% higher than native type A.7Clostridium botulinum. The transport protein according to claim 1 , wherein said transport protein binds to a nerve cell with a higher affinity than native type A.8Clostridium botulinum. The transport protein according to claim 1 , wherein the H-fragment corresponding to amino ...

Iron oxide nanoparticles and methods of use thereof

The presently disclosed subject matter relates to iron oxide nanoparticle compositions and formulations thereof for: (1) the treatment and elimination of biofilms; (2) the prevention of biofilm formation; (3) biofilm extracellular matrix degradation; (4) the inhibition of bacterial viability and growth within the biofilm; and (5) the prevention of tooth or apatitic demineralization. In particular, the presently disclosed subject matter provides a composition for the prevention and treatment of an oral disease (e.g., dental caries) that includes one or more iron oxide nanoparticles and hydrogen peroxide.

Cartilage product

The present invention relates to a method for preparing a cartilage product comprising a protein hydrolysate with a degree of hydrolysis comprised between 0.5% and 3.0%, at least one glycosaminoglycan and at least one growth factor. The present invention also relates to the cartilage product obtainable through said method. Said cartilage product is useful in the treatment or prevention of wounds, ulcers, burns, psoriasis, osteoarthritis, synovitis, osteoporosis, osteopenia, diseases of the tendons and ligaments, periodontal diseases, signs of skin aging, the harmful effects of ultraviolet radiation exposure or stretch marks.

COMPOSITIONS FOR HUMAN DENTAL CARE

Compositions of the invention are water-based formulas that contain natural ingredients which aid in reduction of bacteria in the mouth, thereby reducing plaque and the production of tartar, and in one aspect of the invention are formulated as potable dental water that may be consumed in place of regular consumption of other forms of water or liquid, and in another aspect of the invention are formulated as dentifrices, such as toothpaste. 120-. (canceled)21. An aqueous surfactant-containing composition providing dental plaque reduction in humans , comprising:water in an amount of from 70% to 90% by volume;a synergistic combination of plaque-reducing surfactant agents comprising yucca extract, cinnamon extract and clove extract; andat least one active ingredient selected to reduce the proliferation of bacteria in a human mouth, said at least one active ingredient comprising at least one enzyme.22. The aqueous surfactant-containing composition according to claim 21 , wherein said combination of plaque-reducing surfactant agents comprises 0.01% to 1.0% by volume of yucca extract claim 21 , 0.01% to 0.5% by volume of clove extract and 0.01% to 0.5% by volume of cinnamon extract.23. The aqueous surfactant-containing composition according to claim 21 , further comprising at least one adhering agent for imparting the composition with the ability to coat a mouth cavity and teeth.24. The aqueous surfactant-containing composition according to claim 23 , wherein said at least one adhering agent is selected from the group consisting of glycerin claim 23 , guar gum claim 23 , locust bean gum claim 23 , xanthan gum and carrageenan gum claim 23 , or combinations thereof.25. The aqueous surfactant-containing composition according to claim 21 , further comprising at least one antioxidant agent.26. The aqueous surfactant-containing composition according to claim 25 , wherein said at least one antioxidant agent is selected from the group consisting of grape skin extract claim 25 , ...

ANTI-DANDRUFF HAIR CARE PRODUCTS WITH SELECTED ACTIVE INGREDIENTS AND A CATIONIC KERATIN

The present invention relates to hair treatment agents containing selected alkyloligoglucosides and a selected cationic keratin hydrolysate. A need exists to further improve hair care products and to impart further advantageous properties to them. In particular, a care-providing complex should be made available that ideally can be used even in conjunction with oxidizing agents and surfactant agents. 1. A cosmetic composition , comprising , in a suitable cosmetic carrier , based in each case on the total weight of the composition:a) at least one cationic alkyloligoglucoside, in a total quantity from 0.01 to 10.0 wt %,b) at least one selected cationic keratin hydrolysate, in a total quantity from 0.01 to 10.0 wt %.3. The cosmetic composition according to claim 1 , wherein the cationic keratin hydrolysate corresponds to formula (I) R′—X—R″ (I) claim 1 ,{'sup': +', 'III', 'IV', 'III', 'IV, 'sub': 2', '3', '2', '2, 'in which R′ denotes a lauryl group and X denotes —NRR— with Rdenoting —CHand Rdenoting —CH—CH(OH)—CH—, and R″ denotes a hydrolysate obtained from cortex and/or cuticle of keratinic fibers.'}4. The cosmetic composition according to claim 2 , wherein the quaternary ammonium compound is selected from Stearamidopropyldimethylamine and/or Distearoylethyl Hydroxyethylmonium Methosulfate and/or Dicocoyl Hydroxyethylmonium Methosulfate and/or Dipalmitoylethyl Dimonium Chloride and/or Quaternium-27 and/or Quaternium-91 and/or Behenoyl PG-Trimonium Chloride.6. The cosmetic composition according to claim 1 , further comprising at least one zwitterionic and/or amphoteric surfactant.7. The cosmetic composition according to claim 6 , wherein the zwitterionic and/or amphoteric surfactant is selected from cocamidopropyl betaine and/or Coco Betaine.8. The cosmetic composition according to claim 1 , further comprising at least one active substance selected from coenzyme Q-10 claim 1 , ectoin claim 1 , a purine and derivatives thereof claim 1 , or physiologically acceptable ...

REGENERATING COMPOSITION WITH SMOOTHING ACTION FOR TREATING SKIN IMPERFECTIONS AND PROCESS FOR PREPARATION THEREOF

Disclosed is a regenerating composition having skin lifting and anti-age effect based on chlorinated derivatives of acetic acid, propylene glycol and sodium hydroxide, for use in the treatment of skin blemishes caused by stretch marks, acne scars, sun damage, skin sagging, hyperpigmentation, scars in various parts of the body, such as face, neck, chest, breast, inner thighs, arms, mons pubis, labia majora, inguinal and perianal areas, which is capable of overcoming the problems which are still present in the products of the prior art, a process of preparing the composition, and a method of use. 1) A composition comprising a mixture of one or more chlorinated derivatives of acetic acid , and a glycolic solvent , buffered with a basic compound , to obtain a final pH value of the composition between 2.0 and 4.0 , wherein the glycolic solvent is propylene glycol and the basic buffering agent is sodium hydroxide , for use in regenerating treatments having skin lifting and anti-age effects , for the treatment of skin imperfections.2) The composition according to claim 1 , wherein the chlorinated derivative of acetic acid is: trichloroacetic acid (TCA) claim 1 , dichloroacetic acid (DCA) claim 1 , monochloroacetic acid (MCA).3) (canceled)4) The composition according to having a pH between 2.0 and 3.0.5) The composition according to claim 1 , wherein the mixture of one or more chlorinated acids of acetic acid is in a concentration ranging between 1% and 50% by weight of total composition claim 1 , the glycolic solvent is in a concentration ranging between 1 and 10% by weight of total composition claim 1 , the sodium hydroxide is in a concentration ranging between 1 and 10% by weight of total composition.6) The composition according to claim 5 , wherein the mixture of one or more chlorinated acids of acetic acid is in a concentration ranging between 25 and 35% by weight of total composition claim 5 , the glycolic solvent is a concentration ranging between 3 and 8% by weight ...

Fungal polypeptides having lysozyme activity

The present invention relates to novel lysozyme enzymes from the genus of Rasamsonia.

ANTI-DRANDRUFF HAIR CARE PRODUCTS WITH SELECTIVE ACTIVE INGREDIENTS AND A CATIONIC KERATIN

Hair treatment agents include selected cationic alkyloligoglucosides, alkyloligoglucosides, selected ester oils, and quaternary ammonium compounds as care-providing substances. 2. The hair treatment agent according to claim 1 , further comprising at least one surfactant selected from zwitterionic and amphoteric surfactants claim 1 , in a total quantity from 0.01 to 5.0 wt %.4. The hair treatment agent according to claim 1 , further comprising at least one fatty alcohol having a number of carbons from 10 to 30 at a concentration of less than 2.0 wt %.5. The hair treatment agent according to claim 1 , wherein no silicone is included.6. The hair treatment agent according to claim 2 , wherein the zwitterionic and/or amphoteric surfactant is selected from cocamidopropyl betaine and coco betaine.7. The hair treatment agent according to claim 1 , further comprising at least one active substance selected from the group consisting of carnitine claim 1 , taurine claim 1 , coenzyme Q-10 claim 1 , ectoin claim 1 , a purine and derivatives thereof claim 1 , and a vitamin of the B series.8. The hair treatment agent according to claim 3 , wherein the cationic surfactant is selected from at least one of stearamidopropyldimethylamine claim 3 , distearoylethyl hydroxyethylmonium metho sulfate claim 3 , dicocoyl hydroxyethylmonium methosulfate claim 3 , dipalmitoylethyl dimonium chloride claim 3 , Quaternium-27 claim 3 , Quaternium-91 claim 3 , and behenoyl PG-trimonium chloride.9. A method for treating keratinic fibers claim 3 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'applying a hair treatment according to onto the keratinic fibers and leaving the hair treatment applied without being rinsed out until the hair is next washed.'} The present invention generally relates to hair treatment agents containing selected cationic alkyloligoglucosides, alkyloligoglucosides, selected ester oils, and further quaternary ammonium compounds as care-providing substances.A need ...

COMPOSITION FOR FACIAL CONTOURING COMPRISING MIXTURE OF BOTULINUM TOXIN AND AIR AND METHOD OF FACIAL CONTOURING USING THE SAME

The present invention provides a composition for facial contouring, comprising a mixture of botulinum toxin and air, and a method of facial contouring using the same. When the mixture of botulinum toxin and air is injected into an SMAS layer, the mixture strengthens the SMAS layer and draws back the galea aponeurotica to effectively lift up the face or change the facial contour, thus effectively enhancing the effect of facial contouring. 1. A composition for facial contouring , comprising a mixture of botulinum toxin and air.2. The composition for facial contouring of claim 1 , wherein the botulinum toxin is botulinum toxin serotype A or B.3. The composition for facial contouring of claim 1 , wherein the botulinum toxin and air are mixed in a volume ratio of 1:0.1 to 1:20.4. The composition for facial contouring of claim 1 , wherein the composition is injected into a superficial muscular aponeurotic system (SMAS) layer.5. The composition for facial contouring of claim 1 , wherein the composition increases contraction of the SMAS layer.6. The composition for facial contouring of claim 1 , wherein the composition is formulated in the form of aerosol.7. The composition for facial contouring of claim 2 , wherein the composition is formulated in the form of aerosol.8. The composition for facial contouring of claim 3 , wherein the composition is formulated in the form of aerosol.9. The composition for facial contouring of claim 4 , wherein the composition is formulated in the form of aerosol.10. The composition for facial contouring of claim 5 , wherein the composition is formulated in the form of aerosol.11. An aerosol spray kit comprising the composition of formulated in the form of aerosol.12. A method of facial contouring claim 1 , comprising injecting a mixture of botulinum toxin and air into a superficial muscular aponeurotic system (SMAS) layer.13. The method of facial contouring of claim 12 , wherein the botulinum toxin and air are mixed in a volume ratio of 1:0.1 ...

DERMAL FILLER

Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin. 1. A method for treating a facial wrinkle by administering to the patient a pharmaceutical composition comprising a botulinum neurotoxin and a viscous carrier for the botulinum neurotoxin , wherein the patient's facial wrinkles are alleviated for a longer period of time than they are by administration of a pharmaceutical composition which does not comprise a botulinum toxin.2. The method of claim 1 , wherein the administering is carried out by local subdermal injection of the pharmaceutical composition.3. The method of claim 1 , wherein the viscous carrier is selected from the group of viscous carriers consisting of hyaluronic acid claim 1 , carbomer claim 1 , polyacrylic acid claim 1 , cellulose polycarbophil claim 1 , polyvinylpyrrolidone claim 1 , gelatin claim 1 , dextrin claim 1 , polysaccharide claim 1 , polyacrylamide claim 1 , polyvinyl alcohol claim 1 , polyvinyl acetate claim 1 , chitosans claim 1 , algenates and derivatives and mixtures thereof.4. The method of wherein the viscous carrier is a hyaluronic acid.5. The method of claim 1 , wherein the period of alleviation of the facial wrinkles is determined by a method chosen for the group of method consisting of facial mould claim 1 , electromyographic (EMG) recording and photography.6. The method of claim 1 , wherein the period of time of alleviation of the facial wrinkles is from about 20% to about 100% longer than the period of time the patient's facial wrinkles are alleviated by administration of a pharmaceutical composition injected in the same volume into the same patient at the same location claim 1 , to treat the same facial wrinkles claim 1 , and which contains the same amount of the botulinum toxin claim 1 , but which does not comprise a viscous carrier.7. The method of wherein the viscous carrier is a non-cross linked hyaluronic acid.8. The method of wherein the hyaluronic acid is a cross linked hyaluronic ...

Nanofibre and Bioactive Compositions and Related Methods

Described herein are compositions in nanofibre form including one or more bioactive compounds releasably incorporated thereon. In one embodiment a composition is described comprising at least one nanofibre and at least one bioactive compound. The nanofibres are formed from a base material that is solubilised with the bioactive or bioactives in an aqueous based solvent solution and the base material and bioactives are together spun via electrospinning to form dry fibres with the bioactives chemically bonded to the nanofibres and the bioactives remaining stable during storage of the composition under ambient conditions substantially free of moisture. On exposure to moisture, the nanofibres dissolve, thereby releasing the bioactives. 1. A composition comprising:at least one nanofibre; andan effective amount of at least one bioactive compound;wherein the nanofibres are formed from a base material that is solubilised with the bioactive or bioactives in an aqueous based solvent solution and the base material and bioactives are together spun via electrospinning to form dry fibres; andwherein the bioactives are chemically bonded to the nanofibres and the bioactives remain stable during storage of the composition under ambient conditions substantially free of moisture; and,on exposure to moisture, the nanofibres dissolve, thereby releasing the bioactives.2. The composition as claimed in wherein the bioactives are stable for at least 8 days when stored at 20° C. in the absence of moisture.3. The composition as claimed in wherein the bioactives are covalently bonded to the nanofibres.4. The composition as claimed in wherein the bioactives are selected from: compounds that have at least one phenolic moiety; enzymes including a polypeptide with one or more tyrosine residues; and combinations thereof.5. The composition as claimed in wherein the bioactives are selected from the following plants claim 1 , parts thereof or extracts thereof: grape seed claim 1 , kiwifruit claim 1 , ...

BOTULINUM NANOEMULSIONS

The embodiment described herein are related nanoemulsions comprising botulinum toxins. In one embodiment, the nanoemulsions are prepared by high pressure microfluidization and comprise a particle size distribution exclusively between 10 and 300 nm. The nanoemulsions contemplated by the present invention are useful for the cosmetic and medical treatment of muscular contracture states. For example, botulinum toxin may relax facial muscles such that skin wrinkles become smoother and less noticeable. Further, the present invention contemplates a cosmetic formulation that may be self-administered, for example, in the privacy of one's home and without medical supervision. 125.-. (canceled)26. A nanoparticle composition comprising a population of particles ,wherein the nanoparticle composition is an oil-in-water or water-in-oil nanoemulsion in that oily particles are dispersed within an aqueous dispersion medium or aqueous particles are dispersed within an oily dispersion medium,wherein a majority of the particles have diameters between approximately 10 and approximately 300 nanometers, andwherein the nanoparticle composition comprises at least one botulinum toxin, a surfactant, an oil, and an aqueous medium.27. The nanoparticle composition of claim 26 , wherein the aqueous dispersion medium is selected from the group consisting of water claim 26 , saline solution claim 26 , phosphate buffered saline claim 26 , short chain alcohols claim 26 , 5% dextrose claim 26 , Ringer's solution claim 26 , lactated Ringer's injection claim 26 , lactated Ringer's plus 5% dextrose injection claim 26 , acylated Ringer's injection claim 26 , and combinations thereof.28. The nanoparticle composition of claim 26 , wherein the surfactant is selected from the group consisting of phosphoglycerides; phosphatidylcholines; dipalmitoyl phosphatidylcholine (DPPC); dioleoylphosphatidyl ethanolamine (DOPE); dioleyloxypropyltriethylammonium (DOTMA); dioleoylphosphatidylcholine; cholesterol; cholesterol ...

MASKING SPRAY

One or more techniques and/or systems are disclosed for a composition or formulation that can be used as a surface applied treatment for reducing odors, enhancing a user experience with pleasant scents, and mitigating skin irritation for items worn close to a user's skin. The composition can comprise a natural astringent, such as witch hazel. Further, the composition can comprise an essential oil, such as lavender, mint, tea tree, grapefruit, ylang ylang, eucalyptus, and vanilla, along with distilled water. These ingredient can be readily mixed together, and packaged in an appropriate container, such as a spray bottle. The composition can be applied to a target surface, such as the inside of a mask, by spraying applying the composition. 1. A composition of a surface applied treatment for a personal use item , comprising:a natural astringent comprising witch hazel in an amount sufficient to provide an astringent action to skin;a natural scent made from an essential oil component comprising at least one essential oil selected from the group consisting of: lavender, mint, tea tree, grapefruit, ylang ylang, eucalyptus, and vanilla; anda diluent comprising distilled water.2. The composition of claim 1 , comprising another scent comprising: vanilla claim 1 , bubble gum claim 1 , orange claim 1 , lemon claim 1 , grape claim 1 , root beer claim 1 , chocolate claim 1 , and/or lime.3. The composition of claim 1 , disposed in a spray bottle.4. The composition of claim 1 , disposed in a two ounce spray bottle.5. The composition of claim 1 , comprising a natural antihistamine comprising one or more of: stinging nettle claim 1 , quercetins claim 1 , bromelain claim 1 , and butterbur.6. A method for making composition of a surface applied treatment for a personal use item claim 1 , the method comprising mixing together:a natural astringent comprising witch hazel in an amount sufficient to provide an astringent action to skin;a natural scent made from an essential oil component ...

System, method, and kit for selecting and preparing customized cosmetics

A kit for preparing a customized cosmetic includes at least one of five cosmetic bases. Each of the five cosmetic bases correspond to at least one of a plurality of primary categories. The kit additionally includes at least one cosmetic active ingredient for admixing with the at least one cosmetic base. The at least one cosmetic active ingredient corresponds to at least one of the plurality of primary categories or at least one of the plurality of secondary categories.

LONG LASTING EFFECT OF NEW BOTULINUM TOXIN FORMULATIONS

The invention relates to the use of an animal-protein-free botulinum toxin composition to treat a disease, disorder or condition in a patient in need thereof whereby the animal-protein-free botulinum toxin composition exhibits a longer lasting effect in the patient compared to an animal-protein-containing botulinum toxin composition. 1. A treatment method , comprising:locally administering a first treatment of a therapeutically effective amount of an animal-protein free botulinum toxin composition; andafter a time interval, locally administering a second treatment of a therapeutically effective amount of an animal-protein free botulinum toxin composition, wherein the time interval is greater than a time interval between a first treatment and a second treatment of a therapeutically effective amount of an animal-protein containing botulinum toxin composition.2. The method of claim 1 , wherein locally administering a first treatment and locally administering a second treatment are by injection at an injection site.3. The method of claim 2 , wherein the injection site for the first treatment and the injection site for the second treatment are the same.4. The method of claim 2 , wherein locally administering by injection comprises locally administering a non-reconstituted liquid claim 2 , animal-protein free botulinum toxin composition.5. The method of claim 2 , wherein locally administering by injection comprises locally administering a reconstituted claim 2 , lyophilized animal-protein free botulinum toxin preparation.6. The method of claim 1 , wherein the time interval between first and second treatments of the animal-protein free botulinum toxin composition is at least about 12 weeks.7. The method of claim 1 , wherein the time interval between first and second treatments of the animal-protein free botulinum toxin composition is greater than about 3 months.8. The method of claim 1 , wherein the time interval between first and second treatments of the animal-protein ...

Prophylactic Kit Apparatus

A prophylactic kit apparatus configured to be used with only a single patient includes a plurality of sealed modules and a housing configured to contain those sealed modules such that only one of the plurality of sealed modules can be removed from the housing at a time. Each of the plurality of sealed modules contains at least one prophylactic agent to be used in service of the patient. These sealed modules are to be used in a particular order and the housing is further configured to facilitate the removal of the sealed modules in only that particular order. 1. A prophylactic kit apparatus configured to be used with only a single patient , comprising:a plurality of sealed modules, each of the sealed modules containing at least one prophylactic agent to be used in service of the patient and wherein the sealed modules are to be used in a particular order in service of the patient;a housing configured to conformally and loosely contain the plurality of sealed modules and having a dispensing slot configured and sized such that only one of the plurality of sealed modules can be removed from the housing at a time and in a particular order, the housing having no other openings of sufficient size to accommodate removal of one of the plurality of sealed modules, the housing further including an integral removable flap that at least partially blocks the dispensing slot and that, when removed from the dispensing slot, fully exposes the dispensing slot to thereby permit no more than one of the sealed modules to be removed from the housing therethrough at a time.2. The prophylactic kit apparatus of wherein the plurality of sealed modules contain prophylactic agents to aid in preventing ventilator-associated pneumonia.3. The prophylactic kit apparatus of wherein the prophylactic agents comprise a set-up kit claim 1 , oral-cleaning instruments claim 1 , and mouthwashes.4. The prophylactic kit apparatus of wherein the mouthwashes comprise at least one of chlorhexidine gluconate ...

Compositions and methods for removing dental calculi

Disclosed are compositions and formulations comprising enzymes or other biocatalyst that cleave surface-accessible DNA polymers and/or glycoprotein carbohydrate chains at galactose residues in dental calculus, and optionally further include one or more proteolytic enzymes, thereby destroying the structural integrity of the calculus, and allowing it to be readily removed without requiring special treatment by a trained dental professional. Also disclosed are methods for removing dental calculus using the disclosed compositions and formulations.

Skin Care Formulation for Treatment of Cellulite

The present invention relates to a skin care formulation that is suitable for the treatment of cellulite.

NOVEL TRYPSIN ISOFORMS AND THEIR USE

The present invention relates to the novel trypsin ZT isoforms. In particular, the invention relates to the use of trypsin ZT isoforms in medical devices, pharmaceuticals and cosmetics. 1. A composition comprising at least one isolated cod trypsin ZT isoform comprising an amino acid sequence according to SEQ ID NO: 2 , or an amino acid sequence with 99% sequence homology or more thereof , together with suitable excipients and carriers , wherein the composition:a) is in a medical device;b) comprises a polyvalent alcohol or polyol;c) is an ointment, gel, cream, lotion, hydrogel or suppository composition; ord) is formulated for oral administration in the form of a tablet, a capsule, a lozenge, a troche, a powder or chewing gum.2. The composition according to claim 1 , wherein the at least one isolated cod trypsin ZT isoform is cod trypsin ZT-1 comprising an amino acid sequence according to SEQ ID NO:2.3. The composition according to claim 1 , wherein the hydrogel comprises a polyol.4. The composition according to claim 3 , wherein said cod trypsin ZT isoform(s) are present in admixture with other cod trypsins.5. The composition according to claim 4 , wherein said cod trypsin ZT isoform(s) comprises at least 5% (w/w) of the total content of cod trypsins in said composition.6. The composition according to claim 1 , wherein the medical device is a pressurized metered-dose inhaler.7. The composition according to claim 1 , wherein the polyvalent alcohol claim 1 , is a812-. (canceled)13. A method of removing dead or peeling skin from otherwise healthy skin comprising administering a composition according to to the skin of a patient.14. A method of improving the appearance of skin comprising administering a composition according to to the skin of a patient.15. The method according to claim 14 , said composition further comprising an additional cosmetically active compound.16. A method of treating disease claim 1 , comprising administering a therapeutically effective amount ...

Injectable Botulinum Toxin Formulations And Methods Of Use Thereof Having Long Duration Of Therapeutic Or Cosmetic Effect

This invention provides novel injectable compositions comprising toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes. The injectable compositions embraced by the invention exhibit one or more advantages over conventional toxin formulations, including reduced antigenicity, a reduced tendency to undergo unwanted localized diffusion following injection, increased duration of clinical efficacy or enhanced potency relative, faster onset of clinical efficacy, and/or improved stability. According to the invention, single treatment of the compositions by injection affords significant clinical responses and at least a 6-month duration of effect in a subject undergoing treatment, as provided by the described treatment methods.

Prophylactic kit apparatus

A prophylactic kit apparatus configured to be used with only a single patient includes a plurality of sealed modules and a housing configured to contain those sealed modules such that only one of the plurality of sealed modules can be removed from the housing at a time. This kit may include a physically-discrete informational patient aid disposed within the housing and having information disposed thereon. By one approach these physically-discrete informational patient aids can have a bookmark form factor. So configured, a medical services provider can readily provide the physically-discrete informational patient aid to a patient to thereby facilitate the patient becoming informed regarding the corresponding prophylactic service with little or no burden on the service provider.

Pharmaceutical composition for treating scars on the skin, and method for treating scars on the skin using same

The present invention relates to a pharmaceutical composition for treating scars on the skin, comprising a mixture of botulinum toxin and air. The mixture of botulinum toxin and air according to the present invention, when injected in the dermis, may temporarily removed the elasticity of the dermis and flatten out the depressed part of the scar, and thus enables elaborate intradermic resection and increases the therapeutic effects of lasers for treating pulsed dye laser or of fractional lasers. Thus, scars on the skin can be effectively improved through a one-time operation without negatively affecting the daily lives of patients.

TOPICAL COMPOSITION

The inventors have observed that aqueous mustard seed extract appears to be cytotoxic to fibroblast cells. The cytotoxicity of the aqueous mustard seed extract appears to abate when the extract is heat treated at 120° C. for 15 minutes. The heat treated aqueous mustard seed extract when combined with exogenous myrosinase is not cytotoxic but can induce a modest increase in HO-1 content in cultured fibroblasts and thus would be expected to be useful in a topical composition for treating/preventing itchy skin, particularly the scalp. This invention thus relates to the provision of a topical composition for treating/preventing itchy skin, particularly the scalp. 2. A topical composition according to claim 1 , wherein the glucosinolate-containing plant material comprises a glucosinolate selected from the group consisting of sinigrin claim 1 , glucoraphanin claim 1 , benzyl glucosinolate claim 1 , phenethyl glucosinolate claim 1 , alpha-naphthyl glucosinolate and mixtures thereof.3. A topical composition according to claim 1 , wherein the glucosinolate-containing plant material does not comprise exclusively glucosinolates bearing a hydroxyl group on the side group.4. A topical composition according to claim 3 , wherein the glucosinolate-containing plant material does not comprise exclusively glucosinolates bearing a hydroxyl group at C2 on the side group.5. A topical composition according to claim 1 , wherein thioglucosidase is the sole enzyme.6. A topical composition according to claim 1 , wherein the pH is at least 3 claim 1 , preferably 3 to 8 claim 1 , most preferably 4 to 7.5.7. A topical composition according to claim 1 , wherein the topical composition comprises substantially no ferrous ions.8. A topical composition according to claim 1 , wherein the topical composition comprises 0.1 to 10 claim 1 , preferably 0.3 to 5 claim 1 , most preferably 0.3 to 3 mM vitamin C.9. A topical composition according to comprising glucosinolate-containing plant material in an ...

Hatching fluid enzymes and uses thereof

The present invention relates to various polypeptides from fish hatching fluid, their encoding nucleic acid sequences, pharmaceutical compositions comprising said polypeptides and nucleic acid molecules and their use in various medical and cosmetic applications to the skin, particularly for moisturizing skin and/or for exfoliation of the horny layer of the skin for treating or preventing skin disorders or conditions in an animal.

COSMETIC PRODUCT

Cosmetic products, comprising a container having a tubular body, the wall of which has a transmission for visible light of from 25 to about 100%, and on the top end of which a dispenser head is attached, the dispenser head being bounded below by a movable trailing piston, and a cosmetic preparation in the interior of the container which preparation comprises an outer flowable water-based gel-type phase having a transmission for light of 700 nm wavelength of from 30 to 100% and/or a viscosity of 1000-10,000 mPas at a temperature of 25° C. and a shear rate of approximately 10, and an inner solid particulate phase which comprises substantially spherical particles having an average diameter of from 0.1 to 10 mm, the volume ratio of the inner particulate phase to the outer aqueous gel ranging from about 20%:80% to 74%:26%. 19.-. (canceled)10. A cosmetic product , wherein the product comprises a container and a cosmetic preparation inside the container , the container comprising a tubular body whose walls have a transmittance for visible light of from 25% to about 100% and on whose top end a dispenser head is mounted and which is bounded at its bottom by a movable drawing plunger , and the cosmetic preparation comprising (i) an external fluid gel phase on aqueous basis having a transmittance for light of a wavelength of 700 nm of from 30% to 100% and/or having a viscosity at 25° C. and a shear rate of about 10 of from 1 ,000 to 10 ,000 mPas , and optionally comprising customary auxiliaries and or adjuvants which are dispersible or soluble in water , and (ii) an internal solid particulate phase comprising substantially spherical particles whose average diameter is from 0.1 mm to 10 mm , a volume ratio (ii) (i) ranging from about 20%:80% to 74%:26%.11. The product of claim 10 , wherein the volume ratio (ii):(i) ranges from about 30%:70% to 65%: 35%.12. The product of claim 10 , wherein the volume ratio (ii):(i) ranges from about 40%:60% to 60%:40%.13. The product of claim ...

NOVEL RECOMBINANT BOTULINUM TOXIN WITH INCREASED DURATION OF EFFECT

This invention relates to novel recombinant clostridial neurotoxins exhibiting an increased duration of effect without a delayed onset of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a domain consisting of proline, alanine, serine, threonine, glycine and glutamate residues, and the methods comprise the steps of inserting a nucleic acid sequence coding for said domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising said domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with an increased duration of effect without a delayed onset of effect. 1. A recombinant clostridial neurotoxin comprising at least one domain wherein said domain comprises an amino acid sequence consisting of at least 50 amino acid residues , selected from proline , alanine , serine , threonine , glycine and glutamate residues.2. The recombinant clostridial neurotoxin of claim 1 , wherein said at least one domain comprises an amino acid sequence consisting of between 50 and 500 amino acid residues claim 1 , more particularly between 70 and 300 amino acid residues claim 1 , particularly 100 amino acid residues claim 1 , 150 amino acid residues claim 1 , or 200 amino acid residues.3. The recombinant clostridial neurotoxin of claim 1 , wherein said at least one domain is inserted at a position selected from (i) the N-terminus of the light chain of said recombinant clostridial neurotoxin; (ii) the C-terminus of the light chain of said recombinant clostridial neurotoxin; (iii) the N-terminus of the heavy chain of said recombinant ...

Methods for Treating Cellulite

The invention relates to the discovery that collagenase injections are effective in dissolving and lysing the collagenase septa network in the skin that comprises cellulite. As such, the invention relates to methods of treating cellulite in a patient in need of such treatment comprising injecting or otherwise delivering the effective amount of purified collagenase to the collagenase septa network of cellulite in the skin. The invention also relates to the use of collagenase in the manufacture of a medicament to treat cellulite of the skin. 1. A method of treating cellulite in a subject in need of such treatment , the method comprising delivering an effective amount of purified collagenase to the collagenous septa network of cellulite.2Clostridium hisolyticum.. The method according to claim 1 , wherein the collagenase (Clostridiopeptidase A) is derived from the bacterium3. The method according to claim 1 , wherein the purified collagenase is administered alone.4. The method according to claim 1 , wherein the purified collagenase is administered in an absence of traimcinolone or other corticosteroids.5. The method according to claim 1 , wherein the purified collagenase is injected in a dose comprising at least about 700 SRC units claim 1 , applied in one or more injections.6. The method according to claim 1 , wherein the purified collagenase is injected in a dose comprising at least about 1000 SRC units claim 1 , applied in one or more injections.7. The method according to claim 1 , wherein the purified collagenase is injected in a dose comprising at least about 1500 SRC units claim 1 , applied in one or more injections.8. The method according to claim 1 , wherein the purified collagenase is injected in a dose comprising at least about 10000 ABC units claim 1 , applied in one or more injections.9. The method according to claim 1 , wherein the purified collagenase is injected in a volume of about 1.0 ml.10. The method according to claim 1 , wherein the purified ...

MODULATING EPIGENETIC DNA METHYLATION TO CAUSE CELLS TO ADOPT DNA METHYLATION PATTERNS ASSOCIATED WITH YOUNG CELLS

Disclosed herein is a topical composition that contains (a) a plant meristem conditioned nutrient medium derived from the plants of the genus (b) a preservative present at an amount sufficient to provide sterilizing or biostatic efficacy with respect to component (a); and (c) a dermatologically acceptable vehicle. When topically applied to mammalian cells, the composition of the invention can influence the epigenetic methylation of the DNA such that the methylation state is modulated to have more characteristics and patterns of the epigenetic state of younger cells. 1. A topical composition comprising:(a) a rice plant meristem undifferentiated cell suspension extract, wherein said extract is derived from said rice plant meristem, said extract comprising at least one secondary metabolite, selected from the group of secondary metabolites consisting of flavonoids, carotenoids, protease-inhibitors, phytic acids, alkaloids, terpenoids, glycosides, phenols, polyketides, and polyphenols; wherein said secondary metabolite is water soluble;(b) a preservative present in an amount sufficient to provide sterilizing or biostatic efficacy with respect to component (a); and(c) a dermatologically acceptable vehicle;wherein component (a) is present in an amount of 0.001 percent to 25 percent by weight of the composition, component (b) is present in an amount of 0.5 percent to 1 percent by weight of the composition, and component (c) is present in an amount of 1 percent to 98 percent by weight of the composition.2. The composition of wherein component (b) is present in an amount of 0.75 percent to 1 percent by weight of the composition.3. The composition of wherein the preservative is selected from the group consisting of salicylic acid claim 2 , sorbic acid claim 2 , phenoxyethanol claim 2 , benzyl alcohol claim 2 , ethanol claim 2 , quaternium-15 claim 2 , glucose oxidase and lactoperoxidase in combination with a substrate claim 2 , and combinations thereof.4. The composition of ...

HYDROLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM

Provided are hydrolases, including lipases, saturases, palmitases and/or stearatases, and polynucleotides encoding them, and methods of making and using these polynucleotides and polypeptides. Further provided are polypeptides, e.g., enzymes, having a hydrolase activity, e.g., lipases, saturases, palmitases and/or stearatases and methods for preparing low saturate or low trans fat oils, such as low saturate or low trans fat animal or vegetable oils, e.g., soy or canola oils. 1. An isolated , synthetic or recombinant variant polypeptide comprising an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO:2 , and contains at least one amino acid residue substitution modification relative to SEQ ID NO:2 , selected from the group consisting of: Y7R , D16M , G27Q , G27S , L43V , G45A , G45L , A48T , S54H , D61A , D61E , D61S , V62E , V62A , V62G , V62M , V62N , V62Q , V62S , V62T , R72E , R72K , R72P , R72S , R72T , R72Y , F74I , F74L , F74P , F74R , G77P , G80P , V83C , V83M , D84V , R89S , A96C , A96I , A96S , G98A , G98L , Y113F , E116A , E116F , E116G , E116H , E116L , E116P , E116Q , E116R , E116S , E116T , E116V , K120I , K120L , K120F , K120M , K120S , K146A , I147F , I147L , I151A , I151G , I151H , I151P , I151S , I151T , T155C , D157S , D157G , D268T , N158A , L159M , P160T , I167R , I167S , R172P , R172Q , R172S , D197K , A210V , A211T , A211S , A211I , S212C , S212A , S212E , S212G , S212H , S212L , S212P , S212Q , S212R , S212T , S212V , S212W , S212Y , K213I , K213G , K213T , T214V , T214P , T214N , T214R , T214Y , G215A , G215H , G215S , G215M , G215V , G215P , G215C , G215W , A216T , A216R , A216Y , A216V , A216C , A216C , A216S , A216L , E217Q , E217R , E217S , E217A , E217G , E217P , A218M , A218H , A218Q , A218R , A218W , A218W , A218S , A218T , A218T , A218K , V223A , V223M , V223R , V223T , V223T , V223F , A224F , A224G , A224I , A224Q , A224Y , A225G , A225L , A225M , A225Q , and A225T , and the variant polypeptide ...

Cell Penetrating Peptide, Conjugate Comprising Same, and Composition Comprising Conjugate

The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 156, a fragment of any one sequence of SEQ ID NO: 1 to SEQ ID NO: 156, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed. 1. A conjugate of a cell penetrating carrier peptide and an active ingredient , wherein the carrier peptide comprises of any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 47 and from SEQ ID NO:49 to SEQ ID NO: 156 , the peptide having above 80% homology with the above-mentioned peptide sequences , or the fragment of the above mentioned peptides , andwherein the peptide having above 80% homology with the sequence, and the fragment are the peptides that maintain cell penetrating ability of any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 47 and from SEQ ID NO:49 to SEQ ID NO: 156.2. The conjugate according to claim 1 , wherein the fragment is made of at least 3 amino acids.3. The conjugate according to claim 1 , wherein the carrier peptide is made of 30 or less amino acids.45-. (canceled)6. The conjugate according to claim 1 , wherein the active ingredient is at least one selected from protein claim 1 , nucleic acid claim 1 , peptide claim 1 , lipid claim 1 , glycol-lipid claim 1 , mineral claim 1 , sugar claim 1 , nano-particle claim 1 , biological products claim 1 , contrast agent claim 1 , drugs and chemical compounds.7. The conjugate according to claim 1 , wherein the carrier peptide and the active ingredient are combined via a covalent bond claim 1 , selectively mediated by a linker.8. The conjugate according to claim 1 , wherein the carrier peptide and the active ingredient are combined via non-covalent bond.9. (canceled)10. The conjugate according to claim 6 , wherein the active ingredient is ...

CHITOSAN -AMELOGENIN HYDROGEL FOR IN SITU ENAMEL GROWTH

A composition for re-constructing enamel-coated substrates such as a tooth which includes an amelogenin, chitosan, and water. The composition may also include compounds providing calcium and phosphate ions. Methods using the composition are also provided. 1. A method for treating dental caries , early dental carious and erosive lesions , and enamel defects resulting from genetic diseases comprising: an amelogenin;', 'a chitosan;', 'water;', 'a sufficient amount of a pH adjusting component such that the composition has a pH greater than about 6.0; and, 'a) contacting an enamel coated substrate with a composition includingb) allowing the composition to air dry to form an organized mineral layer over the enamel coated substrate.2. The method of wherein the amelogenin is present in an amount from about 0.03 percent to about 0.4 percent of the total weight of the composition and the chitosan is present in an amount from about 0.2 to about 3 percent of the total weight of the composition.3. The method of further comprising:a calcium-containing compound that provides calcium ion when dissolved in water; anda phosphate-containing compound that provides phosphate ions when dissolved in water.4. The method of wherein the calcium-containing compound is present in an amount from about 0.01 percent to about 0.2 percent of the total weight of the composition and the phosphate-containing compound is present in an amount from about 0.01 percent to about 0.2 percent of the total weight of the composition.5. The method of further comprising contacting the enamel coated substrate with a base for a first period of time.6. The method of further comprising contacting the enamel coated substrate with a component selected from the group consisting of calcium-containing compound claim 5 , a phosphate containing compound claim 5 , and combinations thereof for a second period of time.7. The method of further comprising contacting the enamel coated substrate with saliva or a solution including ...

BOTULINUM TOXIN PREFILLED PLASTIC SYRINGE

The present invention relates to a prefilled plastic container, such as a plastic syringe, comprising an aqueous botulinum toxin formulation. The aqueous botulinum toxin formulation in the prefilled plastic container is stable for a prolonged time period. Furthermore, the present invention relates to a kit comprising the prefilled plastic container, and to the use of the prefilled plastic container for therapeutic and cosmetic purposes. 1. A prefilled plastic container comprising an aqueous botulinum toxin formulation , wherein the toxin activity is not reduced by more than 25% , relative to the initial toxin activity , upon storage of the prefilled container for 12 months at 5° C. or 3 months at 25° C.2. The prefilled plastic container of claim 1 , wherein the number of sub-visible particles of equal to or greater than 10 μm is below 1000/ml during storage for 6 to 24 months at 2° C. to 25° C.3. The prefilled plastic container of claim 1 , wherein the pH value is not increased or decreased by more than 10% claim 1 , relative to the initial pH value claim 1 , during storage of the prefilled container for 6 to 24 months at 2° C. to 25° C. claim 1 , or wherein the pH of the aqueous botulinum toxin formulation during storage is maintained in the range of 6.1 to 7.3 claim 1 , or both.4. The prefilled plastic container of claim 1 , wherein the botulinum toxin is present in the aqueous formulation at a concentration of 10 U/ml to 1000 U/ml.5. The prefilled plastic container of claim 1 , wherein the aqueous botulinum toxin formulation in the prefilled container does not contain a buffer.6. The prefilled plastic container of claim 1 , wherein the container is (i) a syringe claim 1 , (ii) a vial claim 1 , (iii) a carpule claim 1 , or (iv) an ampoule.7. The prefilled plastic container in the form of a prefilled plastic syringe of comprising:(a) a plastic syringe barrel including a proximal end and a distal end, and a generally cylindrical wall extending therebetween and ...

COMPOSITIONS CONTAINING ONE OR MORE POLY ALPHA-1,3-GLUCAN ETHER COMPOUNDS

Compositions comprising cellulase and at least one poly alpha-1,3-glucan ether compound having a degree of substitution with an organic group of about 0.05-3.0 are disclosed. Such compositions can be dry or aqueous, the latter of which can have a viscosity of at least about 10 cPs. The disclosed composition can be in the form of a personal care product, household product, or industrial product, for example. Also disclosed are a method for preparing an aqueous composition comprising cellulase and a poly alpha-1,3-glucan ether compound, and a method of treating a material such as fabric by contacting it with this aqueous composition. 2. The composition of claim 1 , wherein the compound is substituted by the organic group claim 1 , and the organic group is selected from the group consisting of carboxy alkyl claim 1 , hydroxy alkyl claim 1 , and alkyl.3. The composition of claim 2 , wherein the organic group is selected from the group consisting of carboxymethyl claim 2 , hydroxypropyl claim 2 , dihydroxypropyl claim 2 , hydroxyethyl claim 2 , methyl claim 2 , and ethyl.4. The composition of claim 2 , wherein the organic group is a carboxymethyl group.5. The composition of claim 1 , wherein the composition is in the form of a personal care product claim 1 , household product claim 1 , or industrial product.6. The composition of claim 5 , wherein the composition is a fabric care product.7. The composition of claim 1 , wherein the composition is an aqueous composition.8. The composition of claim 7 , wherein the composition has a viscosity of at least about 10 centipoise.10. The method of claim 9 , wherein said cellulase is:(i) comprised in the aqueous composition prior to said contacting step, or(ii) added to the aqueous composition during or after said contacting step.11. The method of claim 9 , wherein:(i) the viscosity of the aqueous composition is increased by said poly alpha-1,3-glucan compound, and/or(ii) the shear thinning behavior or the shear thickening behavior ...

Method And Compositions For Improving Selective Catabolysis in Cells Of Keratin Surfaces

A skin care composition for stimulating selective catabolysis in cells of keratin surfaces comprising at least one autophagy activator and at least one proteasome activator, and a method for improving selective catabolysis in cells of keratin surfaces by treating with the composition.

Pharmaceutical composition comprising a mixture of carboxylated oligopeptides

A pharmaceutical composition comprising a mixture of carboxylated oligopeptides, derived by hydrolysis of eukaryotic or prokaryotic cells and their subsequent partial carboxylation through acylation or alkylation of the amino acid and basic amino acid residues in the amino terminal structure of the oligopeptides. The resulting pharmaceutical composition can be used in production of medical drugs effective in the treatment of cancer, pancreatitis, viral infection, for the development of vaccines.

DEPILATORY COMPOSITIONS

The present invention is directed to a depilatory composition which comprises a depilatory active and at least one material which alters the thermal properties of the composition by either having a higher heat of fusion or a lower thermal conductivity than the bulk. 1. A depilatory composition comprising:bulk composition having a heat of fusion and a thermal conductivity;a depilatory active; anda material that alters the thermal properties of the composition;wherein the material has one or both a higher heat of fusion or a lower thermal conductivity than the bulk composition.2. The depilatory composition as claimed in claim 1 , wherein the material is selected from the group consisting of a phase changing material claim 1 , a micro-encapsulated phase changing material claim 1 , a silica and silicate-based insulator.3. The depilatory composition as claimed in claim 1 , wherein the material comprises a phase changing material selected from the group consisting of organic claim 1 , inorganic materials claim 1 , and mixtures thereof.4. The depilatory composition as claimed in claim 3 , wherein the phase changing material is selected from the group consisting of a mixture of saturated hydrocarbons claim 3 , fatty acids claim 3 , fatty alcohols claim 3 , and esters thereof.5. The depilatory composition as claimed in claim 1 , wherein the material comprises an encapsulated phase-changing material selected from the group consisting of saturated hydrocarbons claim 1 , fatty acids claim 1 , fatty alcohols claim 1 , fatty esters claim 1 , and hydrated inorganic salts.6. The depilatory composition as claimed in claim 1 , wherein the material comprises a silica-based insulator selected from the group consisting of silica aerogels and fumed silica material.7. The depilatory composition as claimed in claim 1 , wherein the material comprises a silicate-based insulator selected from the group consisting of a mica claim 1 , a clay claim 1 , and kaolin.8. A method of removing hair ...

TYROSINASE ACTIVITY INHIBITOR AND EXTERNAL PREPARATION FOR SKIN

A tyrosinase activity inhibitor is prepared by combining (A) a metal (zinc, cobalt or iron) chelate compound of α-lipoyl amino acid or its pharmaceutically acceptable salt with (B-1) a human manganese SOD or (B-2) an ascorbic acid compound such as ascorbic acid and ascorbyl glucoside. A ratio (R1) of the (B-1) component content to the (A) component content is preferably 0.001 to 1,500, when R1 is defined as R1=[Unit concentration of (B-1) component (unit/mL)/Concentration of (A) component (μg/mL)], and a ratio (R2) of the (A) component content to the (B-2) component content is preferably 0.0001 to 1,000, when R2 is defined as R2=[Concentration of (A) component (m/mL)/Concentration of (B-1) component (mg/mL)]. An external preparation for skin contains the (A) component and the (B-1) component or the (B-2) component as effective ingredients for inhibiting tyrosinase activity. 2. The tyrosinase activity inhibitor according to claim 1 , wherein the amino acid constituting the α-lipoyl amino acid is an aliphatic amino acid claim 1 , a cycloaliphatic amino acid claim 1 , an aromatic amino acid or an aminoalkane sulfonic acid.3. The tyrosinase activity inhibitor according to claim 1 , wherein the amino acid constituting the α-lipoyl amino acid is methionine claim 1 , histidine claim 1 , phenylalanine claim 1 , γ-amino-n-butyric acid claim 1 , 6-aminohexanoic acid claim 1 , anthranilic acid or aminoethanesulfonic acid.4. The tyrosinase activity inhibitor according to claim 1 , wherein the M in the formula (1) is zinc.5Escherichia coli. The tyrosinase activity inhibitor according to claim 1 , wherein (B-1) the human manganese SOD is prepared by DNA recombination technology using or yeast.6. The tyrosinase activity inhibitor according to claim 1 , wherein said (A) component is histidine dithiooctanamide (Na/zinc).7. The tyrosinase activity inhibitor according to claim 1 , wherein the tyrosinase activity inhibitor is a combination of said (A) component and said (B-1) component ...

THERAPEUTIC COMPOSITION WITH A BOTULINUM NEUROTOXIN

The present invention pertains to pharmaceutical compositions which comprise botulinum toxin from . The pharmaceutical compositions of the instant invention are not only free of a mammalian derived proteinaceous stabilizing agent but are free of any stabilizing protein. 1Clostridium botulinumClostridium botulinum. A pharmaceutical composition comprising botulinum toxin complexes from of type A , B , C1 , D , E , F or G or a mixture of two or more toxin types , a non-proteinaceous stabilizing agent for the botulinum toxin complexes selected from hyaluronic acid , polyvinylpyrrolidone and polyethyleneglycol , and , optionally , a pH buffer and/or a cryoprotectant , wherein the pharmaceutical composition is free of any stabilizing protein.2. The pharmaceutical composition of claim 1 , which comprises a pH buffer.3. The pharmaceutical composition of claim 2 , wherein the pH buffer is sodium acetate.4. The pharmaceutical composition of claim 1 , which comprises a cryoprotectant.5. The pharmaceutical composition of claim 4 , wherein the cryoprotectant is a polyalcohol.6. The pharmaceutical composition of claim 5 , wherein the polyalcohol is selected from one or more of inositol claim 5 , mannitol claim 5 , and sorbitol.7. The pharmaceutical composition of claim 4 , wherein the non-proteinaceous stabilizing agent is hyaluronic acid claim 4 , and wherein the composition is freeze-dried.8. The pharmaceutical composition of claim 1 , wherein the stabilizing protein is a mammalian derived protein.9. The pharmaceutical composition of claim 1 , wherein the stabilizing protein is selected from serum albumin and gelatin.10Clostridium botulinumClostridium botulinum. A method for stabilizing botulinum toxin complexes from of type A claim 1 , B claim 1 , C1 claim 1 , D claim 1 , E claim 1 , F or G or a mixture of two or more toxin types claim 1 , comprising intermixing the botulinum toxin complexes with a non-proteinaceous stabilizing agent selected from hyaluronic acid claim 1 , ...

INJECTION COMPOSITION COMPRISING HYALURONIDASE FOR REMOVAL OF TOPICAL FAT

The present invention relates to an injection composition comprising hyaluronidase for topical fat reduction. More particularly, the present invention relates to an injection composition comprising 300 IU to 600 IU of hyaluronidase and a local anesthetic, an antihistamine, a lipolysis stimulator and a collagen production stimulator. The present invention promotes the reduction of topical fat tissue, thereby improving obesity and helping weight loss and maintenance of body shape while preventing side effects or skin imbalance by the even removal of fat. Further, at the same time, the present invention can achieve a skin lifting effect where skin resilience is maintained by the stimulation of collagen production. 1. An injection composition for topical fat removal comprising 300 IU to 600 IU of hyaluronidase and, based on the weight of the total composition, 0.08 to 0.4% by weight of lidocaine as local anesthetic, 0.01 to 0.02% by weight of pheniramin as antihistamine, 0.01 to 4.0% by weight of L-carnitine as lipolysis stimulator, and 0.1 to 2.0% by weight of vitamin C as collagen production stimulator, with the remainder being saline solution, wherein the composition is characterized as being injected at a unit volume of 0.5 to 2 cc with an interval between injection points of 0.5 to 1.5 cm. The present application claims priority from Korean Patent Applications No. 10-2016-0116462 filed on Sep. 9, 2016, the entire subject matter of which is incorporated herein by reference.The present invention relates to an injection composition comprising hyaluronidase for the removal of topical fat. More specifically, the present invention relates to an injection composition comprising 300 IU to 600 IU of hyaluronidase and one or more local anesthetics, antihistamines, lipolysis stimulators and collagen production stimulators. Further, the present invention relates to a method for a reduction of topical fat by injecting an injection composition comprising 300 IU to 600 IU of ...

Compositions Comprising A Sirt6 Activator As A Component Of A Yeast Ferment Extract And A DNA Repair Enzyme

Compositions of the invention comprise 8-oxoguanine glycosylase (OGG1) and SIRT6 activating peptide G-A-G-V-S-A-E-NH. Compositions of the invention exhibit anti-aging effects by promoting the repair of skin cell DNA and/or by protecting skin cell DNA from UV damage. The invention is in the field of treatments for improving the appearance of aging skin. More specifically, the invention pertains to topical compositions and methods that promote the protection and/or repair of DNA in skin cells damaged by ultraviolet light.Sirtuins are enzymes that play critical roles in many cellular epigenetic or metabolic pathways. In mammalian cells, seven sirtuin homologs have been identified, referred to as SIRTUINS 1-7 or SIRT1-7. SIRT6 is localized in the cell nucleus (of human keratinocytes and dermal fibroblasts, for example) and is a member of the conserved family of sirtuin proteins which are associated with metabolism and longevity. SIRT6 is a histone 3, lysine 9 (H3K9) deacetylase, and is primarily involved in DNA repair and telomere stability.The term “SIRT6 activating peptide” means a peptide that causes the amount of SIRT6 in the cell to increase by whatever pathway causes that result. US2011-0318284, which is hereby incorporated by reference in its entirety, discloses compositions comprising SIRT6 activating peptides. The peptides are derived from highly conserved regions of human SIRT proteins. Of the eight peptide sequences disclosed in US2011-0318284, the following sequence is of interest here:Note that the NHgroup on the C-terminal end of the peptide has been substituted onto the peptide to improve the resistance of the peptide to certain forms of degradation. NHin that position does not occur naturally.This peptide was reported to increase sirtuin 6 expression very significantly in normal human fibroblasts and normal human keratinocytes in short-term cultures. In addition, the sirtuin 6 expression stimulation effect was maintained for the long term. According to ...

Detergent Compositions

The present invention relates to detergent compositions comprising a variant of a parent lipase which variant has lipase activity, has at least 60% but less than 100% sequence identity with SEQ ID NO: 2, and comprises substitutions at positions corresponding to T231R+N233R and at least one or more (e.g., several) of D96E, D111A, D254S, G163K, P256T, G91T, and G38A of SEQ ID NO: 2. The present invention also relates to use of the compositions, methods of producing the compositions, and methods of cleaning. The present invention furthermore relates to variants and polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides. 1. A detergent composition comprising a variant of a parent lipase which variant has lipase activity , has at least 60% but less than 100% sequence identity with SEQ ID NO: 2 , and comprises substitutions at positions corresponding to T231R+N233R and at least one or more of D96E , D111A , D254S , G163K , P256T , G91T and G38A of SEQ ID NO: 2.2. The composition of further comprising substitutions at positions corresponding to D27R and N33Q of SEQ ID NO: 2.3. The composition of claim 1 , further comprising one or more enzymes selected from: hemicellulases claim 1 , peroxidases claim 1 , proteases claim 1 , cellulases claim 1 , xylanases claim 1 , lipases claim 1 , phospholipases claim 1 , esterases claim 1 , cutinases claim 1 , pectinases claim 1 , mannanases claim 1 , pectate lyases claim 1 , keratinases claim 1 , reductases claim 1 , oxidases claim 1 , phenoloxidases claim 1 , lipoxygenases claim 1 , ligninases claim 1 , pullulanases claim 1 , tannases claim 1 , pentosanases claim 1 , malanases claim 1 , R-glucanases claim 1 , arabinosidases claim 1 , hyaluronidase claim 1 , chondroitinase claim 1 , laccase claim 1 , chlorophyllases claim 1 , amylases claim 1 , or mixtures thereof.4. The composition of claim 1 , wherein said variant in comparison with the parent lipase has increased ...

Cosmetic Compositions for Skin Health and Methods of Using Same

The topical cosmetic compositions and methods of the subject invention can be used to treat and/or prevent a variety of skin conditions, including, for example, age spots, acne, scars, body odor, aging-related conditions (e.g., wrinkles, looseness and dryness), and scalp issues (e.g., dandruff, seborrheic dermatitis and hair loss). In preferred embodiments, the compositions according to the subject invention comprise biological amphiphilic molecules produced by microorganisms. 1. A topical cosmetic composition for treating and/or preventing a skin condition , the composition comprising a therapeutically effective amount of a biosurfactant produced by a microorganism and/or an enzyme produced by a microorganism , and a topically-acceptable vehicle: wherein the biosurfactant is a mannosylerythritol lipid, a sophorolipid, a trehalose lipid, a rhamnolipid, a surfactin, an iturin, and/or a fengycin,', 'wherein the enzyme is an exo-beta-1,3-glucanase, esterase, lipase, glycosidase, amylase, protease, and/or chitinase, and', {'i': Starmerella bombicola, Wickerhamomyces anomalus, Pichia guilliermondii, Pseudomonas chlororaphis, Rhodococcus erythropolis Pseudozyma aphidis, Bacillus amyloliquefaciens', 'Bacillus subtilis., 'wherein the microorganism is a or'}], 'and'}2. (canceled)3. The composition of claim 1 , comprising 0.01% to 1.0% mannosylerythritol lipids and 0.01% to 1.0% sophorolipids claim 1 , by weight.4. (canceled)5. The composition of claim 1 , further comprising a protein claim 1 , amino acids and/or peptides produced by the microorganisms.6. The composition of claim 1 , further comprising a therapeutically effective amounts of one or more of resveratrol claim 1 , hyaluronic acid and polyacrylic acid.7. The composition of claim 1 , further comprising a therapeutically effective amounts of a comedolytic or anti-acne agent.8Aloe vera. The composition of claim 1 , further comprising a therapeutically effective amounts of extract.9. The composition of claim 1 , ...

METHODS AND KITS FOR TOPICAL APPLICATION, REMOVAL, AND INACTIVATION OF THERAPEUTIC OR COSMETIC TOXIN COMPOSITIONS

This invention relates to methods and kits for safely removing and inactivating topical therapeutic or cosmetic compositions. The methods and kits according to the invention are particularly well suited for removing and inactivating highly toxic substances. 134-. (canceled)35. A method for removing a topically applied neurotoxin from a surface on a patient , the method comprising:removing neurotoxin from the area with a removal agent; andinactivating the removed neurotoxin with an inactivation agent.36. The method according to claim 35 , wherein the neurotoxin is selected from the group consisting of botulinum toxin claim 35 , tetanus toxin claim 35 , saxitoxin claim 35 , and tetrodotoxin.37. The method according to claim 36 , wherein the toxin is botulinum toxin.38. The method according to claim 37 , wherein the botulinum toxin comprises botulinum toxin serotype A.39. The method according to claim 38 , wherein the botulinum toxin is a purified botulinum toxin molecule.40. The method according to claim 35 , wherein the step of removing the toxin comprises wiping off the toxin.41. The method according to claim 35 , wherein the step of inactivating the removed neurotoxin comprises one or more of the following(1) combining the removed neurotoxin with a composition comprising an oxidizer;(2) exposing the removed neurotoxin to an inactivation agent comprising electromagnetic radiation for photochemically degrading the neurotoxin;(3) exposing the removed neurotoxin to an inactivation agent comprising a basic agent; or(4) exposing the removed toxin to heat sufficient to thermally degrade the toxin.42. The method according to claim 41 , wherein the oxidizer is biodegradable.43. The method according to claim 41 , wherein oxidizer comprises sodium hypochlorite in powder form.44. (canceled)45. (canceled)46. The method according to claim 41 , wherein the electromagnetic radiation comprises ultraviolet radiation.47. (canceled)48. (canceled)49. (canceled)50. (canceled)51. The ...

Encapsulates

The present application relates processes that can be used to produce encapsulated benefit agents comprising a core and a shell that encapsulates said core, encapsulated benefit agents produced by such process and products comprising such encapsulated benefit agents as well as methods of making and using such products. Such process can be used to produce particles that offer the desired protection and release benefits when used in a varity of products. 1. A population of encapsulated benefit agents having a population diameter coefficient of variation from about 6% to about 50% , said population of encapsulated benefit agents comprising encapsulated benefit agents having a mean diameter of from about 3 micrometers to about 300 micrometers , said encapsulated benefit agent comprising a core and a shell that encapsulates said core , said shell comprising a polymer , said shell having a thickness of from about 0.5 micrometers to about 15 micrometers and a shell thickness coefficient of variation from about 2% to about 30%.2. A population of encapsulated benefit agents according to wherein said shell comprises a film forming polymer.3. A population of encapsulated benefit agents according to having a population diameter coefficient of variation from about 8% to about 35% claim 1 , said population of encapsulated benefit agents comprising encapsulated benefit agents having a mean diameter of from about 5 micrometers to about 240 micrometers claim 1 , said encapsulated benefit agent comprising a core and a shell that encapsulates said core claim 1 , said shell comprising a polymer claim 1 , said shell having a thickness of from about 1 micrometer to about 8 micrometers claim 1 , and a shell thickness coefficient of variation from about 4% to about 25%.4. A population of encapsulated benefit agents according to having a population diameter coefficient of variation from from about 12% to about about 25% claim 3 , said population of encapsulated benefit agents comprising ...

HAIR CARE PRODUCTS WITH SELECTED QUARTERNARY AMMONIUM COMPOUNDS AND SILICONES CONTAINING SUGAR STRUCTURES

The present invention relates to hair treatment agents containing selected quaternary ammonium compounds and silicones containing sugar structures. 2. The cosmetic composition according to claim 1 , further comprising at least one zwitterionic and/or amphoteric surfactant.3. The cosmetic composition according to claim 2 , characterized in that the zwitterionic and/or amphoteric surfactant is at least one surfactant selected from the group consisting of cocamidopropyl betaine and coco betaine.5. The cosmetic composition according to claim 1 , further comprising at least one silicone selected from the group consisting of dimethicones claim 1 , dimethiconols claim 1 , cyclomethicones claim 1 , amodimethicones claim 1 , and dimethicone copolyols.6. The cosmetic composition according to claim 1 , characterized in that the quaternary ammonium compound is selected from Stearamidopropyldimethylamine and/or Distearoylethyl Hydroxyethylmonium Methosulfate and/or Dicocoyl Hydroxyethylmonium Methosulfate and/or Dipalmitoylethyl Dimonium Chloride and/or Quaternium-27 and/or Quaternium-91 and/or Behenoyl PG-Trimonium Chloride.7. The cosmetic composition according to claim 1 , characterized in that the cationic aminosilicone is PEG-8 PG-Coco-Glucoside Dimethicone.8. The cosmetic composition according to claim 1 , further comprising a further cationic surfactant selected from the group consisting of Behentrimonium Chloride and cetyltrimethylammonium chloride.9. The cosmetic composition according to claim 1 , further comprising at least one amino acid selected from the group consisting of alanine claim 1 , arginine claim 1 , asparagine claim 1 , aspartic acid claim 1 , cysteine claim 1 , cystine claim 1 , citrulline claim 1 , glutamic acid claim 1 , glutamine claim 1 , glycine claim 1 , histidine claim 1 , hydroxylysine claim 1 , hydroxyproline claim 1 , isoleucine claim 1 , leucine claim 1 , lysine claim 1 , methionine claim 1 , phenylalanine claim 1 , proline claim 1 , serine ...

COSMETIC COMPOSITION COMPRISING A COLLAGEN PROTECTING OR ENHANCING AGENT AND PARTICLES COMPRISING SILICA AND TITANIUM DIOXIDE TOPICAL COMPOSITIONS

The present invention relates to a topical composition comprising at least one collagen protecting and/or collagen enhancing agent and a silica-titanium dioxide composite particle having a particle size D0 of greater 0.3 μm, a D100 of less than 35 μm and a D50 of 4.0 to 10 μm, wherein the silica-titanium dioxide composite particle consists of 20-45 wt.-% titanium dioxide particles having a particle size D50 of 100 to 300 nm embedded in a matrix of silica. Furthermore the invention relates to the use of such silica-titanium dioxide composite particles to ameliorate the sensory properties of a topical composition comprising collagen protecting agent and/or collagen enhancing agent as well as to reduce the short and long term eye contour puffiness, dark eye circles, crow's feet and fine lines. 1. A topical composition comprising at least one collagen protecting and/or collagen enhancing agent , wherein the composition further comprises a silica-titanium dioxide composite particle having a particle size D0 of greater 0.3 μm , a D100 of less than 35 μm and a D50 of 2.0 to 10 μm , wherein the silica-titanium dioxide composite particle consists of 20-45 wt.-% of titanium dioxide particles having a particle size D50 of 100 to 300 nm embedded in a matrix of silica.2. The topical composition according to claim 1 , wherein the amount of the silica-titanium dioxide composite particle is selected in the range of 0.1-5 wt.-% based on the total weight of the cosmetic composition.3. The topical composition according to claim 1 , wherein the particle size D50 of the silica-titanium dioxide composite is selected in the range of 3 to 6 μm claim 1 , the particle size D50 of the titanium dioxide particles is selected in the range of 200-250 nm and the amount of titanium dioxide particles embedded in the matrix of silica is selected in the range of 27-35 wt.-%.4. The topical composition according to claim 1 , wherein the silica-titanium dioxide composite particle has a refractive index ...

REDUCED-COST COSMETIC FORMULATIONS THAT REDUCE VISIBLE SIGNS OF AGEING

The present invention discloses a number of formulations (including some that comprise Lunasin and reduce the visible signs of ageing by reducing skin wrinkles) that can be used as body-wash and related skin and hair treatments that can be manufactured using high quality ingredients at a reasonable cost, lower than comparable available products. 1. A cosmetic skin-care formulation designed to reduce skin wrinkles , specifically excluding cocamidopropyl betaine , and comprising the following amounts of components measured as weight-percent:Lunasin from 0.1% to 40%, wherein the Lunasin is extracted using cold pressing,Argon Oil from 0.1% to 5%,A rheology modifier from 0.3% to 1.4%C14-16 alpha olefin sulfonate from 1% to 4%Decyl Glucoside from 4% to 16%Sodium Benzoate from 0.1% to 0.4%Potassium Sorbate from 0.1% to 0.4%EDTA from 0.1% to 0.2%Imidazolidinyl urea from 0.1% to 0.6%Niacinamide from 0.01% to 1%Allantoin from 0.1% to 0.4%Glycerine from 0.5% to 2%Polyquaternium-10 from 0.1% to 0.4%and water to 100%.2. A cosmetic skin-care formulation of comprising:Lunasin 5%, wherein the Lunasin is extracted using cold pressing,Argon Oil from 0.1%A rheology modifier 0.3%C14-16 alpha olefin sulfonate 1%Decyl Glucoside 4%Sodium Benzoate 0.1%Potassium Sorbate 0.1%EDTA 0.1%Imidazolidinyl urea 0.1%Niacinamide 0.01%Allantoin 0.1%Glycerine 0.5%Polyquaternium-10 0.1%and water to 100%.3. The cosmetic skin-care formulation of consisting of the following amounts of components measured as weight-percent:Lunasin from 1.0%-20%, wherein the Lunasin is extracted using cold pressing,Argon Oil from 0.1% to 0.2%,A rheology modifier, 0.7%-0.8%C14-16 alpha olefin sulfonate, 2.0%-3.0%Decyl Glucoside, 8.0%-9.0%Sodium Benzoate, 0.2%-0.3%Potassium Sorbate, 0.2%-0.3%EDTA, 0.1%-0.2%Imidazolidinyl urea, 0.3%-0.4%Niacinamide, 0.2%-0.3%Allantoin, 0.2%-0.3%Glycerine, 1.0%Polyquaternium-10, 0.2%-0.3%and water, to 100%4. The cosmetic skin-care formulation of additionally consisting of: Sodium Cocoyl ...

MUCOADHESIVE DEVICES FOR THE RELEASE OF PROBIOTICS AND FOR THE MAINTENANCE OF THEIR ENZYME ACTIVITIES

The present invention relates to medical devices in the form of mucoadhesive films for the release of live lactic bacteria and bifidobacteria (probiotics) and/or for the release and maintenance of their pharmacologically useful enzyme activities. 1. An article of manufacture comprising a mucoadhesive film , the article of manufacture comprising:{'i': 'Bifidobacterium', '(a) one or more bacterial strains of lactic bacteria and one or more bifidobacteria of the genus ; and/or'}{'i': 'Bifidobacterium,', '(b) one or more enzymes derived from said one or more bacterial strains of lactic bacteria and one or more bifidobacteria of the genus'}wherein said mucoadhesive film films being characterised in that the one or more bacterial strains of lactic bacteria, the bifidobacteria and/or the one or more enzymes derived from said one or more bacterial strains of lactic bacteria or one or more bifidobacteria are present on only one of the surfaces of the mucoadhesive film.2. The article of manufacture of claim 1 , in which the mucoadhesive film has a thickness of about ≤1 mm and the quantity of the one or more bacterial strains of lactic bacteria and the one or more bifidobacteria on the film's surface is between about 10and 10cfu/cm.3. The article of manufacture of claim 1 , wherein: the{'i': Lactobacillus acidophilus, Lactobacillus buchneri, Lactobacillus brevis, Lactobacillus casei, Lactobacillus catenaforme, Lactobacillus cellobiosus, Lactobacillus crispatus, Lactobacillus curvatus, Lactobacillus delbrueckii, Lactobacillus jensenii, Lactobacillus leichmanii, Lactobacillus minutus', 'bacillus plantarum Lactobacillus rogosae, Lactobacillus salivarius, Lactobacillus reuteri, Lactobacillus rhamnosus', 'Bifidobacterium animalis', 'lactis', 'Bifidobacterium adolescentis, Bifido', 'bacterium angulatum, Bifidobacterium bifidum, Bifidobacterium catenulatum, Bifidobacterium dentium, Bifidobacterium eriksonii, Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium plantarum, ...

COMPOSITIONS AND METHODS TO PREVENT AND TREAT BIOFILMS

Compositions and methods to treat biofilms are disclosed based on the discovery of the role of the disaccharide trehalose in microbial biofilm development. In various embodiments to treat body-borne biofilms systemically and locally, the method includes administering trehalase, the enzyme which degrades trehalose, in combination with other saccharidases for an exposition time sufficient to adequately degrade the biofilm gel matrix at the site of the biofilm. The method also includes administering a combination of other enzymes such as proteolytic, fibrinolytic, and lipolytic enzymes to break down proteins and lipids present in the biofilm, and administering antimicrobials for the specific type(s) of infectious pathogen(s) underlying the biofilm. Additionally, methods are disclosed to address degradation of biofilms on medical device surfaces and biofilms present in industrial settings. 1. A method for treating the formation and growth of a biofilm comprising sulfate reducing bacteria on a substrate , comprising:contacting the substrate with a composition comprising 3 ppm to 30 ppm of trehalase and 50 to 100 ppm of a non-oxidizing biocide.2. The method of wherein the non-oxidizing biocide comprises tetrakis hydroxymethyl phosphonium sulfate (TRPS).3. The method of wherein the non-oxidizing biocide comprises a biocide selected from the group consisting of glutaraldehyde claim 1 , dibromonitriloproprionamide (DBNPA) claim 1 , polyhexamethylene biguanide (PHMB) claim 1 , methylene bis(thiocyanate) (MBT) claim 1 , 2-(thiocyanomethylthio)benzothiazole (TCMTB) claim 1 , bronopol claim 1 , 2-bromo-2-nitro-1 claim 1 ,3-propanediol (BNPD) claim 1 , tributyl tetradecyl phosphonium chloride (TTPC) claim 1 , taurinamide and derivatives thereof claim 1 , phenols claim 1 , quaternary ammonium salts claim 1 , quinaldinium salts claim 1 , lactones claim 1 , organic dyes claim 1 , thiosemicarbazones claim 1 , quinones claim 1 , carbamates claim 1 , urea claim 1 , salicylamide claim 1 ...

KITS AND METHODS OF USING HYALURONIDASE TO MODIFY POLYSACCHARIDE FILLERS AND DELIVERY SYSTEMS

Embodiments of the present invention are directed to kits, compositions and methods for modifying and altering polysaccharide fillers and drug delivery systems with the application of hyaluronidase 116-. (canceled)17. A drug delivery system comprising a polysaccharide and hyaluronidase held in a vessel for reconstitution.18. The drug delivery system of claim 17 , wherein said polysaccharide has one or more sugars selected from the group consisting of D-galactose and 3 claim 17 , 6-anhydro-L-galactopyranose.19. The drug delivery system of claim 18 , wherein said polysaccharide is an agarose.20. The drug delivery system of claim 17 , further comprising one or more drugs.21. The drug delivery system of claim 20 , wherein one or more drugs are selected from anesthetic agents claim 20 , aesthetic agents claim 20 , or combination thereof.22. The drug delivery system of claim 17 , wherein the hyaluronidase render the polysaccharide in a more fluid state upon reconstitution.23. The drug delivery system of claim 17 , wherein the polysaccharide comprises agarose and neoagarosehexaose.24. A kit for performing dermal filling procedures comprising:a. a polysaccharide for forming a mass in the body of an animal, wherein said polysaccharide has one or more sugars selected from the group consisting of D-galactose and 3, 6-anhydro-L-galactopyranose; andb. an hyaluronidase for altering said polysaccharide, for administration with said polysaccharide or to said mass held in the body to effect a modification of said mass.25. The kit of claim 24 , wherein said hyaluronidase is recombinant.26. The kit of claim 24 , wherein said polysaccharide is an agarose.27. The kit of claim 26 , wherein the agarose further comprises neoagarosehexaose. This application claims priority to U.S. Provisional Application Ser. No. 62/460,756, filed on Feb. 18, 2017, the contents of which are incorporated herein by reference.Embodiments of the present invention were not conceived or reduced to practice with ...

COMPOSITION FOR REMOVING DENTAL PLAQUE AND TARTAR

The present disclosure relates to formulation for a teeth-cleaning product and a process for creating the formulation. Coconut milk and citrus pith are mixed into a formulation and heated upon a heat source until substantially boiling. Sodium bicarbonate and sodium carbonate are mixed into the formulation. Next, ethanol and hydrogen peroxide are added to the formulation. The formulation is removed from the heat source, then apple flesh and sodium chloride are added to the formulation. The formulation is allowed to cool. Next, peppermint oil and honey are added. 1. A method for creating a formulation for cleaning teeth from a set of ingredients having a cumulative weight , the method comprising:adding an amount of coconut milk ranging from about 14 percent to about 50 percent by weight of the cumulative weight to the formulation;adding an amount of pith from one or more citrus fruits ranging from about 10 percent to about 72 percent by weight of the cumulative weight to the formulation;heating the formulation in a container via a heat source until the formulation reaches a first temperature at which the formulation is boiling;boiling the formulation for a first amount of time ranging from about one minute to about thirty minutes;adding an amount of sodium bicarbonate ranging from about 2 percent to about 15 percent by weight of the cumulative weight to the formulation;adding an amount of sodium carbonate ranging from about 2 percent to about 15 percent by weight of the cumulative weight to the formulation;agitating the formulation to mix in the sodium bicarbonate and the sodium carbonate;boiling the formulation for a second amount of time ranging from about one minute to about fifteen minutes;adding an amount of ethanol ranging from about 0.1 percent to about 13 percent by weight of the cumulative weight to the formulation;boiling the formulation for a third amount of time ranging from about 20 seconds to about five minutes;adding an amount of hydrogen peroxide ...

COMPOSITIONS FOR TREATMENT OF XEROSTOMIA AND FOR TOOTH TREATMENT

The present application provides an oral care composition comprising: 1. An oral care composition comprising:a) emu oil;and one or more of the following:b) one or more emulsifying agents;c) one or more protease enzymes;d) one or more soluble calcium phosphate remineralizing agents;e) one or more whitening agents.2. The composition of comprising:a) emu oil;and two or more of the following:b) one or more emulsifying agents;c) one or more protease enzymes;d) one or more soluble calcium phosphate remineralizing agents;e) one or more whitening agents.3. The composition of comprising:a) emu oil;and three or more of the following:b) one or more emulsifying agents;c) one or more protease enzymes;d) one or more soluble calcium phosphate remineralizing agents;e) one or more whitening agents.4. The composition of comprising:a) emu oil;b) one or more emulsifying agents;c) one or more protease enzymes;d) one or more soluble calcium phosphate remineralizing agents;e) one or more whitening agents.5. The composition of claim 4 , wherein one or more of the protease enzymes are selected from the group consisting of papain claim 4 , trypsin claim 4 , chymotrypsin claim 4 , aminopeptidase claim 4 , carboxypeptidase claim 4 , pepsin claim 4 , and cathepsin.6. The composition of claim 4 , wherein the one or more whitening agents are selected from the group consisting of carbamide peroxide and hydrogen peroxide.7. The composition of claim 4 , wherein the one or more soluble calcium phosphate remineralizing agents are selected from the group consisting of dibasic calcium phosphate claim 4 , monocalcium phosphate claim 4 , tricalcium phosphate claim 4 , and tetracalcium phosphate.8. The composition of claim 7 , wherein the one or more emulsifying agents are phospholipids.9. The composition of claim 8 , wherein the phospholipids are lecithin.10. The composition of claim 4 , wherein the composition further comprises an isomalt.11. The composition of claim 10 , wherein the isomalt is selected ...

METHOD FOR CONDITIONING SKIN BY USING EARTHWORM PROTEIN

A method for conditioning skin is provided, which comprises applying to a subject in need an effective amount of a composition, wherein the composition comprises earthworm protein. The method is especially for reducing the concentration of erythema on skin and/or decreasing the size of pores on skin. 1. A method for conditioning skin , comprising applying to a subject in need an effective amount of a composition , wherein the composition comprises earthworm protein.2. The method as claimed in claim 1 , wherein the composition is applied as a solution claim 1 , an emulsion claim 1 , or a paste.3. The method as claimed in claim 1 , wherein the concentration of the earthworm protein (as dry powders) in the composition is about 0.005 to 0.05 wt %.4. The method as claimed in claim 1 , wherein the composition is applied to the subject in form as at least one of a mask claim 1 , a lotion claim 1 , a cream claim 1 , an emulsion claim 1 , a foundation cream claim 1 , a foundation liquid claim 1 , a sunscreen claim 1 , and a bath preparation.5. The method as claimed in claim 1 , wherein the earthworm protein is obtained by extracting earthworms with water.6. The method as claimed in claim 5 , wherein the earthworm protein is obtained by extracting earthworms with warm water of about 40 to 50° C.7Pheretima aspergillumE. PerrierPheretima vulgarisEisenia rosea savigny, Eisenia Foetida, Pheretima pectiniferaPhererima guillelmi.. The method as claimed in claim 5 , wherein the earthworm is at least one of () claim 5 , Clen claim 5 , claim 5 , and8Pheretima aspergillumE. PerrierPheretima vulgarisEisenia rosea savigny, Eisenia Foetida, Pheretima pectiniferaPhererima guillelmi.. The method as claimed in claim 6 , wherein the earthworm is at least one of () claim 6 , Clen claim 6 , claim 6 , and9. The method as claimed in claim 1 , wherein the method is for reducing the concentration of erythema on skin and/or decreasing the size of pores on skin.10. The method as claimed in claim 9 , ...

MIXTURE TO INCREASE THE EFFECTIVENESS OF ANTISEPTICS AND/OR DISINFECTANTS, AN AGENT CONTAINING THE MIXTURE, AND THE USE OF THIS MIXTURE

The invention relates to the increase (improvement) of the effectiveness of antiseptics and/or disinfectants administered in a mixture with hydrolytic or proteolytic enzymes to a mucous membrane, a skin of a mammal or inanimate surfaces in the form of a solution, gel, paste, capsules or other as an agent. The use of the mixture is also stated. 115-. (canceled)16. An antiseptic or a disinfectant composition comprising chlorhexidine digluconate in an amount of 0.001% to 1% by weight and proteolytic or hydrolytic enzyme in an amount of 0.01% to 2% by weight based on the total weight of the composition and further comprising buffered saline and water.17. The antiseptic or a disinfectant composition according to claim 16 , wherein the amount of chlorhexidine digluconate is 0.01% to 0.12% by weight and the amount of proteolytic or hydrolytic enzyme is 0.01% to 0.4% by weight based on the total weight of the composition.18. The antiseptic or a disinfectant composition according to claim 16 , comprising two different enzymes.19. The antiseptic or a disinfectant composition according to claim 18 , wherein the two different enzymes are each a hydrolytic enzyme.20. The antiseptic or a disinfectant composition according to claim 19 , wherein the hydrolytic enzyme is selected from protease claim 19 , lipase or amylase.21. The antiseptic or a disinfectant composition according to claim 16 , comprising two hydrolytic enzymes claim 16 , wherein the two hydrolytic enzymes are both proteases claim 16 , lipases or amylases.22. The antiseptic or a disinfectant composition according to claim 21 , wherein the protease is selected from the group consisting of trypsin claim 21 , chymotrypsin claim 21 , bromelain and papain.23. The antiseptic or a disinfectant composition according to claim 22 , wherein the amount of chlorhexidine digluconate is 0.001% to 1% by weight claim 22 , the amount of trypsin or chymotrypsin is 0.01% to 0.2% by weight and the content of bromelain is 0.01% to 0.4% by ...